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Abstract 
The accurate prediction of solubility of drugs is still problematic. It was thought for a long time that shortfalls 
had been due the lack of high-quality solubility data from the chemical space of drugs. This study considers the 
quality of solubility data, particularly of ionizable drugs. A database is described, comprising 6355 entries of 
intrinsic solubility for 3014 different molecules, drawing on 1325 citations. In an earlier publication, many 
factors affecting the quality of the measurement had been discussed, and suggestions were offered to improve 
ways of extracting more reliable information from legacy data. Many of the suggestions have been 
implemented in this study. By correcting solubility for ionization (i.e., deriving intrinsic solubility, S0) and by 
normalizing temperature (by transforming measurements performed in the range 10-50 °C to 25 °C), it can now 
be estimated that the average interlaboratory reproducibility is 0.17 log unit. Empirical methods to predict 
solubility at best have hovered around the root mean square error (RMSE) of 0.6 log unit. Three prediction 
methods are compared here: (a) Yalkowsky’s general solubility equation (GSE), (b) Abraham solvation equation 
(ABSOLV), and (c) Random Forest regression (RFR) statistical machine learning. The latter two methods were 
trained using the new database. The RFR method outperforms the other two models, as anticipated. However, 
the ability to predict the solubility of drugs to the level of the quality of data is still out of reach. The data quality 
is not the limiting factor in prediction. The statistical machine learning methodologies are probably up to the 
task. Possibly what’s missing are solubility data from a few sparsely-covered chemical space of drugs 
(particularly of research compounds). Also, new descriptors which can better differentiate the factors affecting 
solubility between molecules could be critical for narrowing the gap between the accuracy of the prediction 
models and that of the experimental data.  
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Introduction 
In pharmaceutical research, the aqueous solubility of exploratory compounds is a very important 
physical property to assess [1,2]. Peroral drugs with very low solubility may not release sufficient 
compound from the solid form during the intestinal transit to generate therapeutic benefit. Conversely, 
highly water-soluble drugs may not be able to permeate lipoidal barriers in the intestinal wall and in the 
barriers beyond, to reach the therapeutic site of action in sufficient concentration. Thus, not too little and 
not too much solubility is an important balancing act in compound advancement during drug development. 
Alex Avdeef  ADMET & DMPK 8(1) (2020) 29-77 
30  
Given the large number of compounds tested in drug discovery, measurement of solubility is done by 
high-throughput methods, which generate “kinetic” values in buffers containing 0.5-5 %v/v DMSO [2,3]. 
Usually, amorphous solids precipitate from supersaturated solutions in the microtitre wells. Although 
kinetic solubility can be 10-100 times higher than equilibrium solubility, it is nevertheless suitable for 
anticipating whether a particular test compound will precipitate in an in-vitro bioassay, triggering a false 
positive test [3-6]. Compounds advanced into later stages of research are fewer in number. Justifiably, 
more rigorous methods are used to measure their equilibrium solubility, often in media more reflective of 
the biological fluids to which drugs are exposed [7]. 
It is beneficial to predict equilibrium solubility of research compounds at the start of discovery projects, 
as part of virtual screening of compound libraries, before any actual measurements are done, for assisting 
in the prioritizing molecules for the project. Numerous methods for predicting solubility of organic 
molecules have been described in the literature, based on quantitative structure-property relationships 
(QSPR), where the molecular structure is used to predict physicochemical properties [8]. 
This study concerns prediction of the equilibrium solubility of drugs. Perhaps, more importantly, the 
focus is on the impact of molecules selected to train the prediction method. The details of the evolving Wiki 
pS0 database (in ADME Research) [9] of druglike molecules will be described. Since 2011, the focused 
searching of the primary literature for equilibrium measurements of aqueous solubility (especially as a 
function of pH) of druglike molecules has contributed to 6355 intrinsic solubility, log S0, entries. The pre-
processing of the available solubility data to extract the underlying S0 values (normalized to 25 °C [10]) 
utilized the purpose-designed computer program, pDISOL-X (in ADME Research) [11] (whose prototype 
FORTRAN version, STBLTY, was first coded in the late 1970s [12]). As part of the curation, data quality was 
assessed by interlaboratory comparisons of those molecules which were studied multiple times by different 
researchers. The log S0 values, along with their estimated standard deviations (SD), were then used to train 
two solubility prediction models: (i) weighted multiple linear regression (MLR) using Abraham solvation 
descriptors [13], and (ii) Random Forest regression (RFR) [14] using the diverse descriptor collection from 
the RDKit open-source chemoinformatics and machine-learning library [15]. The results were compared to 
those calculated by the general solubility equation (GSE), which requires no training [16,17]. Four external 
test sets [18-20] were employed in the validation of the models, taking care to remove any of the test set 
molecules from the large training set. Three of the test sets (containing only druglike molecules) have 
appeared in landmark ‘Solubility challenges’ [19,20]. 
Methods 
Quantitative structure-property relationships (QSPR) models  
General solubility equation (GSE) 
In 1965 Irmann [21] described solubility prediction based on a group contribution approach. For solids, 
he included a term related to the entropy of fusion, coupled with the melting point (Tm). In 1968, Hansch et 
al. [22] recognized that the octanol-water partition coefficients, log P, are strongly correlated linearly with 
aqueous solubility values, log Sw, for nonionizable liquid samples. Expanding on the work of Irmann and 
Hansch, Yalkowsky and coworkers developed and popularized the general solubility equation (GSE), to 
enable the prediction of solubility of liquids and solids in water [16-18,23-27]. Just two variables, Tm (°C) 
and log P, both experimental determined, are used in the equation to predict solubility of organic 
compounds in water (in log molar units): 
 log S = 0.5 - log P - 0.01(Tm - 25) (1)  
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The equation requires no “training.” Although the GSE is rooted in sound thermodynamic principles, 
some assumptions had to be made in developing the equation: test compounds are taken to be nonionized 
and fully-miscible in octanol (leading to the 0.5 intercept term), and that the water and octanol phases are 
assumed not appreciably mutually soluble (but, according to [28]: water-saturated octanol contains ~25 
mol% water; solubility of octanol in water is ~2 mM). The implicit assumption behind the 0.01 factor arises 
from the near constancy of the entropy of fusion. This is in reasonable agreement with the relatively 
nonflexible aromatic solutes initially considered. A semi-empirical version of the GSE was proposed: the 
calculated log P could be used in place of the experimental value. More recently, a version was proposed 
entirely based on calculated descriptors [27]. Empirically-adjusted coefficients in Eq. (1), based on various 
training sets [16,24,29], did not result in substantially improved predictions of the solubility of druglike 
substances. The GSE is popular for its ease of use [17]. 
Yalkowsky and Banerjee [18] proposed an external test set of 21 molecules: 6 solid and 3 liquid poorly-
soluble pesticides (log Sw -3.4 to -7.9), 11 simple drugs (log Sw 0.5 to -4.1), and a laxative/dye molecule (with 
somewhat uncertain solubility). As will be shown below (cf., Fig. 11a), the solubility of the above test set 
molecules is well predicted by Eq. (1). This test set has been widely used by other investigators.  
Empirical prediction models 
Dearden [30], Taskinen and Norinder [31] thoroughly reviewed solubility prediction studies reported 
from 1992 to 2005 [25,29,32-47] which used the popular Yalkowsky-Banerjee external test set to assess the 
efficacy of the empirical methods. The average of the reported prediction root-mean square errors (RMSE) 
is about 0.9 log unit, with individual values found to range from 0.6 to 1.4. The predictions of Raevsky et al. 
[29] (nearest-neighbor method, using HYBOT hydrogen bond descriptors) and Tetko et al. [40] (artificial 
neural network method, with electrotopological E-state indices) fared slightly better than those of others. 
Many of the training sets used in the prediction studies consisted of several hundred simple organic 
molecules, including aromatic hydrocarbons, polyhalogenated organic compounds, practically-insoluble 
agrochemicals and environmental pollutants, many in liquid form at room temperature, but only relatively 
few druglike molecules (resulting in spotty coverage of the chemical space resembling today’s 
pharmaceutical discovery compounds). As summarized in the reviews [30,31], prediction methods included 
multiple-linear regression (MLR), principal components regression (PCR), partial least-squares (PLS), k-
nearest neighbors (kNN), artificial neural networks (ANN), support vector regression (SVR), and Random 
Forest regression (RFR). Some of the QSPR methods were based on hundreds of calculated atomic and 
molecular 2D and 3D descriptors. In many of the studies, the most influential descriptors are two calculated 
physical properties: log P and molar refractivity, MR, (which accounts for molecular size and polarizability). 
Other calculated 2D descriptors included partial-charge surface properties, atom and functional group 
counts, connectivity and topological and electrotopological indices, H-bond donor and acceptor counts; 3D 
descriptors included energy terms (total potential energy, electrostatic, molecular mechanics force-field 
energy), molecular shape, volumes, and water-accessible surface areas [48-55]. 
Wang and Hou [56] summarized solubility prediction efforts up to 2010, comparing the results of 16 
studies. They discussed the improvements resulting from consensus modeling. Also, there was a discussion 
of using “local data” models to improve predictability, with the domain of applicability (DOA) identified by 
molecular descriptor similarity, rather than structural (e.g., Tanimoto indices) similarity. 
Abraham solvation equation (ABSOLV) 
Abraham and Le [13] amended the Abraham solvation equation [57] to predict solubility: 
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log S0 = c0+ c1 A + c2 B + c3 Sπ + c4 E + c5 V + c6 A∙B (2) 
In the MLR equation, the log S0 is the dependent variable (measured log intrinsic molar solubility) and 
the independent variables are the five solute descriptors accounting for the transfer of solute from one 
phase to another: A is the sum of H-bond acidity, B is the sum of H-bond basicity, Sπ is the 
dipolarity/polarizability (subscripted here, so as not to be confused with solubility), E is an excess molar 
refraction in units of (cm3∙mol-1)/10, and V is the McGowan characteristic volume in units of 
(cm3∙mol-1)/100. The c0-c6 coefficients in Eq. (2) are determined by MLR, trained on a set of intrinsic 
solubility values of a diverse collection of molecules. The five Abraham solvation descriptors may be 
calculated from 2D structure (introduced as a SMILES text or as coordinates in a ‘mol’ or ’sdf’ type file) 
using the program ABSOLV [58] (cf., www.acdlabs.com). The A∙B cross-term in Eq. (2) is intended to deal 
with intermolecular H-bond interactions between acid and base functional groups in the solid or liquid 
environment. Its inclusion, as an alternative to using the Tm term in Eq. (1), was intended to improve the 
prediction accuracy. Eq. (2) applied to the Yalkowsky-Banerjee external test set, using the MLR coefficients 
reported by Abraham and Le (their Eq. 11), with ABSOLV-calculated descriptors, resulted in RMSE = 1.71 log 
unit (prostaglandin-E2 was an extreme outlier; data not shown). In the present study, we re-determined 
the seven MLR coefficients using our own training data, with the data weighted according to estimated 
measurement errors, to find a much better fit, as will be shown below (cf., Fig. 12a). 
Random Forest regression 
Of the new machine-learning statistical approaches, the Random Forest regression (RFR) method is 
thought to be among the top performers, in terms of prediction accuracy. The method was introduced in 
2001 by Brieman [14], and is implemented in the open-source “randomForest” library for the R statistical 
software [59-61]. RFR may be appealing to new users because it can be employed “off the shelf,” requiring 
only minimal learning. In many applications, the default “tuning” parameters are nearly optimal. RFR works 
by constructing an ensemble of hundreds of decision trees [62].  
To illustrate, in part, how RFR works, Figure 1 shows an example of a single recursive partition decision 
tree constructed (Algorithm Builder v.1.8, ACD/Labs, Toronto, Canada; www.acdlabs.com), using the 600 
zwitterionic molecules in the Wiki-pS0 database, drawing on the five Abraham descriptors [57]. The process 
begins with the unsupervised selection of one of the descriptors (E in the example) and finding the optimal 
‘splitting’ value (1.27 in the example) which divides the solubility data into two branches: the left branch 
grouping 369 molecules which have descriptors less than the splitting value and the right branch grouping 
231 molecules with descriptors equal to or exceeding the splitting value. A criterion for the splitting can be 
based on minimizing the residual sum of squares at each node,  
RSS = Σi (yi - <yleft>)
2 + Σj (yj - <yright>)
2    (3) 
where i indexes the solubility values in the left branch and j indexes those in the right branch; y represents 
log S0 values; <y> is the average value in the left/right branch. Each of the two branches generates a new 
node. The process then repeats until the “terminal” nodes are reached, associated with a specified 
minimum of molecules (e.g., 5). In the above decision tree training, r2 = 0.70 and RMSE = 0.81 (average of 
the seven terminal “leafs”). Generally, the node splitting procedure yields ever more homogeneous 
groupings of molecules, and produces trees which bring together similar solubility values at the same node. 
The above example involved just one tree, where at each node, all of the descriptors were considered in 
the selection of the one best suited to split the node. RFR is different in a number of ways. Typically, 500 
decision trees – a “forest” – are constructed. 
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Figure 1. Example of a calculated recursive partition decision tree (Algorithm Builder v.1.8), based on 600 
zwitterionic molecules (Wiki-pS0 database), using Abraham descriptors. At each node, all five descriptors are 
queried to select the one best suited for further splitting of the data. In part, node splitting stops at 5 
molecules. By comparison, the Random Forest method uses hundreds of trees (each containing a different 
subset of randomly-selected solubility values of molecules) and re-selects a subset of descriptors randomly 
for each node splitting 
Liaw [61] graphically illustrated the structure of a typical random forest. The entire data matrix 
comprises n rows of solubility values and p columns of chemical descriptors. Each tree in the forest is 
allocated a different bootstrap (with replacement) sample of the n rows – i.e., it contains a randomly-
selected subset (e.g., two thirds) of the entire solubility data. For each tree, the “left out” molecules (e.g., 
one third) are called the ‘out-of-bag’ (OOB) sample. Each tree is grown to its maximum size by node 
splitting, as partly illustrated in Figure 1. In RFR, only a randomly-selected subset of the available 
descriptors (typically, p/3) is used at each node in each tree. Each tree is grown until the terminal nodes are 
reached, with each final “leaf” containing a specified minimum number of solubility values, the average of 
which being the predicted value for the particular tree. The final prediction for the regression model is 
made by averaging predictions from all trees. All the compounds that did not take part of the tree growing 
process (OOB compounds) can be used as an internal validation set to estimate the error of the model. 
To assess the predictability of the models in the current study, we randomly split the solubility data into 
a training set (70 %) and an internal test set (30 %), as described by Walters [63]. Also, external test sets 
proposed by others were predicted based on the RFR model trained with all of the molecules (excluding 
any from the external test sets).  
RFR is not sensitive to the presence of irrelevant descriptors, even those which are highly correlated. 
Hence, “over-fitting” the data is not expected. (However, it is noteworthy that if test set molecules are also 
included in the training set, then their RFR “prediction” will be very close to the user-provided measured 
values.) RFR includes built-in estimation of (i) prediction accuracy (as standard deviation of the predicted 
mean), (ii) descriptor importance (as a result of sensitivity testing of each descriptor), and (iii) similarity 
between molecules (as a result of the node filtering process). The application of the method to QSAR 
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predictions has been described in detail by Svetnik et al. [64]. An inconvenience of the currently-developed 
RFR method is that it cannot extrapolate (in the sense that MLR methods can): it cannot predict any 
solubility value outside of the range encompassed by the training set. For example, the extremely-low 
(log S0 < -8) solubility of drugs like amiodarone, clofazimine, itraconazole, halofantrine, and probucol is not 
expected to be well estimated by RFR. The latter molecules are near the edge of the chemical space 
(defined by the descriptors used) that’s sparsely populated by molecules with similar solubility. The closest 
molecules are likely to be more soluble than the above test compounds.  
The first applications of RFR to predict solubility appeared in 2007 [65,66]. Schroeter et al. [65] used Sw 
and SpH data (mixed values not corrected for ionization) to train a RFR method, using ~4000 measurements 
mostly taken from secondary sources [35,67,68] and some from in-house (Bayer Schering Pharma) sources. 
For the Huuskonen data [35] as test set, RMSE = 0.66 (n=1290) was reported. For the solubility data in the 
domain of applicability (DOA) matching that of research compounds (10-3 to 10-7 M solubility), the RFR 
method indicated RMSE ~ 0.85 log unit. In the Palmer et al. [66] RFR analysis, aqueous solubility values of 
998 structurally diverse druglike solid organic compounds were gathered from similar secondary sources: 
Handbook of Aqueous Solubility [69], Huuskonen [35], and Delaney [47]. (It was not reported how 
molecules were corrected for ionization.) The authors used the molecular operating rnvironment (MOE) 
[70] to generate 126 two-dimensional (log P, MR, charged-surface properties, atom, group, and H-bond 
counts, connectivity and topological indices) and 36 three-dimensional (total potential energy, electrostatic 
contributions, molecular shape, and solvent-accessible surface area) descriptors. Various values of the RFR 
tuning parameters, ntree, mtry, and nodesize, were explored in the model trained with all of the 2D 
descriptors, with the best parameter values found to be ntree = 500, mtry = 42, and nodesize = 5, which are 
the usual default values. The training set of compounds produced the statistics: r2 = 0.98, RMSE = 0.28, n = 
988, bias = 0.007. As often pointed out, this is not an accurate measure of the predictability of solubility of 
molecules not used in the training process. Randomly splitting the entire data into a training set (70 %) and 
an internal test set (30 %) produces a good measure of the ability of the model to predict solubility of 
compounds not included in the training set, indicated r2 = 0.89, RMSE = 0.69, n = 330, bias = 0.017. An 
external test set produced similar statistics. Including the 3D descriptors did not make substantial 
improvements to the model. 
The most influential descriptors in the Palmer et al. study were calculated to be those related to the 
fractional van der Waals surface area, VSA. The ten most important descriptors ranked by RFR were log P > 
negative VSA (PEOE_VSA_FNEG) > number of hydrophobic atoms (a_hyd) > MR > hydrophobic atoms VSA 
(vsa_hyd) > chi1v (topological) > polar VSA (PEOE_VSA_FPOL) > hydrophobic VSA (PEOE_VSA_FHYD) > MW 
> negative polar VSA (PEOE_VSA_FPNEG).  
More recently, Walters [63] thoroughly compared the Huuskonen thermodynamic Sw values (n = 1274) 
[34,35], the Llinas et al. thermodynamic S0 values (n = 94) [19] and PubChem (n=1000) kinetic high-
throughput solubility [71] databases using the RFR framework. The publication serves as a very useful 
tutorial to the machine-learning method, and is highly recommended for those interested to try RFR. 
Gap between prediction and experiment  
For 411 compounds characterized by multi-source solubility measurements, Katritzky et al. [72] found 
standard deviation, SD, to be 0.58 log in replicate values. According to Taskinen and Norinder [31], an 
AstraZeneca in-house database of solubility measurements of different batches of the same compound 
typically showed reproducibility of 0.49 log. Higher uncertainties had been discussed (Jorgensen and Duffy 
[73]; Palmer and Mitchell [74]). It has been a widely-shared view that interlaboratory measurement 
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reproducibility is typically 0.6 log. 
As mentioned previously, the solubility prediction errors are often in the 0.6 to 1.3 log unit range [30,31, 
56,73,74]. So, one might surmise that prediction methods are approaching measurement error limit. But, 
this may not be so. 
First, many of the early prediction studies considered molecules from a chemical space occupied by 
relatively simple organic molecules and some complex agrochemicals, which were adequately represented 
by the then available training set data. In some of these studies, low RMSE were achieved. Earlier training 
sets were under-represented in practically insoluble and highly lipophilic druglike molecules, whose 
physicochemical properties are not easy to measure accurately. In some cases, important descriptors, such 
as calculated log P can be off by 1-2 log units (e.g., amiodarone). Since values of log P > 5 or < -2 are difficult 
to measure accurately by the shake-flask method [28], log P prediction methods can be uncertain for out-
of-bounds molecules. At such extreme values, experimental log P values may not strongly correlate with 
the experimental log S values [75]. Since many of today’s research compounds have very low solubility, the 
earlier prediction methods that have shown low RMSE are not expected to do as well when subjected to 
predicting solubility of practically insoluble drug molecules, such as amiodarone and itraconazole, or novel 
research compounds synthesized in drug discovery programs, for which there may be a shortage of 
prediction training set data publically available. 
Second, the perceived 0.6 log error in measured solubility may be upwardly biased, given how disparate 
legacy data have been handled in assembling large training sets. The relatively poor reproducibility may be 
the result of systematic errors arising from mixing different types of solubility values, measured at different 
temperatures, or simply gathered from poor-quality measurements. A ‘white paper’ drawing on expert 
consensus thoughts of researchers from six countries addressed the critical needs related to experimental 
assay design, and how legacy data can be better processed to reveal improved precision [76]. A related 
study [9] discussed at length the correction of data for ionization when solution complexity distorts the 
expected shape of the log S-pH profile predicted by the Henderson-Hasselbalch equation. When solubility 
values measured in the temperature range 10-50 °C are transformed to values at 25 °C, the estimates of the 
interlaboratory precision improve [10]. 
The above two points suggest that the gap between prediction and experimental errors may still be 
substantial. Similarly, Palmer and Mitchell [74] made the case that it’s not the data that are limiting, but 
rather it’s the prediction methods (and/or descriptors) that need further improvements. In an earlier 
review, Faller and Ertl [77] suggested that “no really satisfactory approach to [drug] solubility prediction is 
available yet,” in spite of the large number of prediction studies. 
Quality and chemical space of experimental data 
It has been consistently shown that the best prediction models are devised from training set molecules 
that occupy very similar chemical space (defined by the descriptors used) as those in the test set [63]. For 
drug solubility prediction, the ideal training sets would consist of molecules of interest to discovery 
projects. Only a tiny fraction of such measurements are publically available, and in-house pharma 
prediction studies are unlikely to be openly publicized.  
Measuring equilibrium solubility of ionizable molecules is expensive and analytical-resource consuming. 
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Factors affecting reproducibility in published solubility data – ‘white paper’ summary  
Many of the factors affecting the quality of equilibrium solubility measurement have been discussed in 
the consensus report (‘white paper’ [76]) are summarized in the list: 
 dissolution of added solid has not reached equilibrium during the selected equilibration time, 
 solid state characterization not performed after equilibration - polymorphs, hydrates, solvates, 
nanoparticles, amorphous forms not identified, 
 formations of drug aggregates/oligomers (dimers, trimers, …), micelles, and drug-buffer complexes in 
solution at equilibrium [78], 
 poor wettability, 
 adsorption to filter/vial surface, 
 inappropriate phase separation methods used, e.g., (i) first centrifuging a saturated solution, then 
filtering the supernatant (without first saturating the filter); (ii) multiple re-centrifuging a centrifuged 
solution (without pre-saturating the vial surfaces); (iii) nano-sized particles passing through filter, 
 using unnecessarily high buffer concentrations, possibly effecting drug-buffer complexation [78], 
 not using buffers with low-soluble ionizable drugs (especially weak bases), 
 effect of impurities unaccounted, especially those which are ionizable when unbuffered solutions are 
used, 
 not measuring the final pH of the equilibrated saturated solution of ionizable drugs (buffered pH may 
be altered by the drug), 
 not taking into account the effect of ambient CO2 on the water solubility of low-soluble bases in 
unbuffered solutions, 
 inadequate pH electrode calibration at low/high pH (junction/asymmetry effects), and in drug-salt 
studies (high ionic strength), 
 compound instability at the extremes of pH or over long saturation times (e.g., indomethacin, 
acetylsalicylic acid, ascorbic acid), 
 stereoisomers (DL-, D-, L-), (R-/S-), or cis-/trans-isomers not stated, 
 limit of detection (LOD) - not sufficiently sensitive analytical methods used to determine drug 
concentration below LOD, 
 for ionizable compounds, inaccurate value of pKa used to calculate log S0 from log S-pH profile 
introduces systematic error. 
The impact of the above factors can be minimized by employing good experimental practices and 
appropriate data analysis methods. However, in today’s solubility prediction methods, factors such as the 
formation of differing polymorphs, hydrates, solvates, amorphous solids, and the impact of stereoisomers, 
are not adequately addressed.  
Data 
Wiki-pS0 database 
The intrinsic solubility database, Wiki-pS0 (in-ADME Research), contains 6355 log S0 (log molar) entries, 
based on measured aqueous solubility values of 3014 different compounds collected from 1325 cited 
references (as of April 2019). In the majority of the cases, the literature data were further processed, using 
pDISOL-X (in-ADME Research), to extract intrinsic solubility (S0) values from reported aqueous free-
acid/base or salt solubilities (Sw), solubilities at specified pH (SpH), or log S-pH profiles [9,11,76,78-81]. All of 
the molecules are solids at room temperature (except for propofol, whose Tm is 14 °C). There are 1078 
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log S0 entries derived from 9907 individual log S measurements at a particular pH (cf., Fig. 1a in [9]). About 
half of the data sources originate from secondary listings and the rest are from primary sources. In the case 
of secondary sources, the citations to the original work are generally available, and in many cases were 
consulted for clarifications. Differently named molecules were identified and reconciled by searching the 
database for matching Tanimoto structural fingerprint indices [15]. 
For 3671 entries, comments were added to the database records (based on available information in the 
original sources), briefly noting experimental method used (mostly saturation shake-flask), temperature 
(23 °C assumed when ‘room temperature’ was stated or no value was provided), equilibration time, 
apparent quality of data, standard deviation in measured values (if reported), buffers/pH, polymorphic or 
hydrate form (if identified), method of solid separation, agitation method, etc. 
The most reliable data had been determined by the saturation shake-flask (SSF) method (still the “gold 
standard” methodology in the minds of most experimentalists), especially when taken as a function of pH. 
Also, two potentiometric instruments have demonstrated their importance: pSOL [82] and CheqSol [83] 
(both now available from Pion Inc., Billerica, MA, USA). The characterization of solid forms (crystalline, 
amorphous, nanoparticle, etc.) and their impact on the measured solubility are important considerations 
(i.e., solvate, polymorph, racemate effects), but these are not always reported/detailed in the solubility 
studies. 
Two websites: ChemSpider (Royal Society of Chemistry, UK) www.chemspider.com, and PubChem 
(https://pubchem.ncbi.nlm.nih.gov/ were valuable for checking names of molecules, obtaining CAS 
numbers, getting structure representations (SMILES), melting points (Tm), and the like. ACD/Labs 
ChemSketch was useful for drawing molecules and constructing SMILES representation for molecules. 
When measured Tm were not found (as in 19 % of the entries in Wiki-pS0), then Lang and Bradley [84] 
predicted Tm were used: QsarDB open repository of data and prediction tools (http://qsardb.org/-
repository/predictor/10967/104?model=rf).  
Data added to Wiki-pS0 from multi-source compilations (‘low hanging fruit’) 
 PHYSPROP database [67] (Sept 1999 version: over 6000 measured water solubility, Sw): 1327 values 
were selected for molecules not appreciably ionized in water. Excluded compounds were: (a) Tm < 
40 °C, (b) log Sw < -8 or > 0, (c) surfactants/long aliphatic chain molecules, (d) polycyclic aromatic 
hydrocarbons, (e) peroxides, (f) carboxylic acids, (g) salts/complexes, (h) dyes or names containing 
color, and (i) herbicides, pesticides, insecticides, rodenticides, and acaricides (as indicated by “tags” at 
the ChemSpider website). Of the selected 1327 compounds, the Sw values of 1210 
nonionizable/nonionized molecules were taken to be S0. The other 117 compounds were processed by 
pDISOL-X to calculate S0 and pHsat (pH of saturated solution) from the given Sw and pKa, assuming pure 
water was the solvent, and the Henderson-Hasselbalch equation was valid [11]. Literature references 
(many from Merck Index and Beilstein – cf., below) were recorded in Wiki-pS0. 
 Handbook of aqueous solubility data [85]: 1130 Sw of druglike molecules were selected, with 776 
values subjected to pDISOL-X analysis to determine S0 values. Some values were listed as intrinsic in 
the handbook, only requiring adjustments when the temperature was not 25 °C. Original references 
were recorded in Wiki-pS0. Many references were checked; however, references for 65 compounds 
could not be accessed online. Occasionally, reported Sw values for neutral compounds were actually 
those of drug-salt measurements, as clarified on checking the original literature. 
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 Beilstein [68] (cf., [67]): Sw values of 474 compounds were used, after conversion to the S0 scale, where 
necessary. 
 Benet-Broccatelli-Oprea 927 BDDCS solubility list [86]. This compilation contains interesting drugs, but 
no references to original sources were cited and no experimental details were given. Of the drug 
solubilities listed, 333 were selected. In many cases, the original sources were recognized on cross 
checking with existing entries in Wiki-pS0. The Sw values were mostly of free bases/acids, but some 
were clearly of salts, which required careful effort to discern. All selected values were converted to the 
S0 scale using pDISOL-X. 
 Analytical profiles of drug substances (APDS) [87]. The first 39 volumes of the series of monographs 
were searched for quantitative solubility data. Monographs on 155 molecules were selected for pre-
processing. Most of the reported solubility values of ionizable molecules were measured in pure water 
with unspecified saturation pH. For those ionizable molecules which were not drug salts, the intrinsic 
values were calculated by pDISOL-X. Unfortunately, the solubility reported in APDS is often devoid of 
experimental detail (e.g., temperature not always reported), some citing ‘personal communication’ as 
references. Nevertheless, there are several high-quality log S - pH original data sets in the monographs. 
 Merck index [88]. Sw values of 173 molecules were used, after conversion to the S0 scale. The Merck 
Index is often cited in older databases (e.g., [67]), but it may not be a sufficiently reliable general 
source for critical studies (literature references not usually given, details often lacking, etc.).  
 Biowaiver monographs for immediate release solid oral dosage forms [89]. Dressman and colleagues 
published a series of papers (2005-2018), from which 14 drug solubility values were added to Wiki-pS0, 
some being not previously-published measurements.  
 Miscellaneous collections: Freier’s book [90] - 96 values were selected; Handbook of Biochemistry [91] 
- 54 values were used; Kühne et al. tabulation [33] - 53 values used; Mullin’s book [92] - 51 values 
used; Raevsky et al. tabulation [29] - 32 values used.  
Single-source measurement of many compounds (‘quick catches’) 
The small single-source databases below consist largely of intrinsic solubility values. Useful collections of 
original measurements included those of McFarland et al. [93], Bergström and coworkers [94-98], and 
Faller and Ertl [77].  
 Avdeef [80] - 39 values, not published elsewhere, were used. 
 Rytting et al. [99] - free-base/acid (no salts used) SSF-measured Sw: solubility of 113 molecules, all 
measured in one laboratory, with S0 calculated by pDISOL-X.  
 CheqSol log S0 at 25 °C (potentiometric) - 233 values for 145 molecules collected from several 
publications: Stuart and Box [83], Sköld et al. [100], Llinàs et al. [19,101], Box and Comer [102], 
Hopfinger et al. [103], Narasimham et al. [104], Hsieh et al. [105], Comer et al. [106], Palmer and 
Mitchell [74], Etherson et al. [107]; Schönherr et al. [108]; Fornells et al. [109], and Baek et al. [110]. 
 pSOL log S0 at 25 °C (potentiometric) – 75 published values were collected: Avdeef [111,112], Avdeef et 
al. [82], Avdeef and Berger [113], Faller and Wohnsland [114], Bergström et al. [115], Fioritto et al. 
[116], and Ottaviani et al. [117].  
Data from miscellaneous primary sources (‘deep-sea fishing’) 
About 2000 solubility values were gathered from various primary (non-database) sources. Those 
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publications which contained measurements as a function of pH were particularly valuable. A large fraction 
of the primary source data originated from a few journals: Int. J. Pharm., J. Pharm. Sci., Pharm. Res., 
J. Chem. Eng. Data, Eur. J. Pharm. Sci., AAPS PharmSciTech, AAPS J, J. Chem. Inf. Comput. Sci., and Ind. Eng. 
Chem. Res. 
Sources of pKa data 
The pKa values of the ionizable molecules were taken from Avdeef [80]; (cf., www.in-
ADME.com/wiki_pka.php/), and various other established sources. When no experimental values were found, 
then the values calculated by MarvinSketch 5.3.7 (ChemAxon Ltd., www.chemaxon.com) were used. The pKa 
values were automatically adjusted for changes in the ionic strength [11,80] and temperature [118] by 
pDISOL-X.  
Units conversion 
Solubility data have been reported in many concentration units: mol/L (molarity, M), mM, μM, mol/kg 
(molality, m), mole fraction (x), mg/mL, μg/mL, mg/100mL, mg/dL, %w/v, g%mL, mg/mL%, mg%, “1 in 15 of 
water,” “soluble in 3 parts of water,” “2 % soluble in water,” units of IU/mL, etc. Mole fraction and molality 
units are almost always used when solubility is determined over a wide range of temperatures, since the 
units do not depend on the density of the solutions. In the clearly presented accounts, the equivalent 
molecular weight to use to convert the practical units (e.g., μg/mL) to molarity is stated (e.g., 
“concentration is expressed as free base equivalent”). In practice, it is all too easy to make a mistake in 
converting the reported units to the preferred molarity scale, so extra care is recommended.  
It could be argued that solubility should be tabulated in logarithmic units (preferably based on molarity). 
(i) Direct values span over 12 orders of magnitude and cannot be accurately depicted in S-pH plots at the 
low end of the scale (sic - log of “zero” solubility is undefined). Unfortunately, raw S-pH data are often 
presented only in a plot, with points plotted at ~zero. (ii) Errors in log S values do not depend on the 
magnitude of the log S (whereas they do when direct units are considered). This is problematic when 
refinement of constants is based on S measurements and unit weights are assumed.  
In the Wiki-pS0 database, values reported in molality units are noted, but are seldom converted to those 
in molarity (by applying solution density), since the differences are small around the temperature range of 
interest, and since solution density is usually not reported. 
Interlaboratory reproducibility  
There are 870 different molecules in Wiki-pS0 for which solubility was reported from at least two 
different sources. This formed the basis for estimating interlaboratory reproducibility. Some molecules had 
been studied in many different laboratories. For example, there were 33 different reports of the solubility 
of diclofenac found to date, with 17 of these measured at several different pH values, whose complicated 
profiles were reconciled and discussed by Bergström and Avdeef [79]. The next most-frequently studied 
molecules are phenytoin, barbital, and ketoprofen, with 30, 26, and 24 interlaboratory determinations, 
respectively. The average interlaboratory reproducibility, SDavg, based on the curated 870 replicated 
studies, has been determined to be 0.17 log unit, significantly lower than the experimental reproducibility 
suggested in past studies (~0.6 log unit) [72-74]. As noted above, many factors can lead to the perception of 
poor reproducibility of measurements. It takes some effort to factor in the possible sources of systematic 
error, to attain the low SDavg. Still, for some difficult-to-measure drug molecules, the intrinsic solubility is 
quite uncertain, with SD values exceeding 0.5 log unit [20,79]. 
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Physicochemical properties of database molecules 
The 6355 intrinsic solubility set ranges in log S0 from -11.0 to +1.8 (log molarity), essentially with a 
Gaussian distribution: mean = -3.04, median = -3.00, SD = 1.88. Figure 2 shows the solubility distribution for 
the molecules. About 47 % of the entries have log S0 between -7 and -3, the typical range (DOA – domain of 
applicability) of values for drugs and research compounds [65]. About 2 % of the molecules have log S0 < -7. 
Some of the least-soluble molecules (log S0 < -8) in the database are amiodarone < clofazimine 
< itraconazole < halofantrine < ubiquinone < epristeride < vinorelbine < silafluofen < cosalane < etretinate < 
probucol < arotinoic acid < clomifene < motretinide < lasalocid < carbenoxolone. The most soluble (log S0 > 









Figure 2. Distribution of intrinsic solubility 
values in Wiki-pS0. 
 
 
Figure 3 shows the trend between measured log S0 and calculated log P (RDKit [15]), the most important 
descriptor in the prediction of solubility. The scatter is substantial, and perhaps trends nonlinearly at the 
extremes of the scales. The measured extreme values of log S0 are possibly more accurate (since these are 
mostly determined from multi-point log S-H profiles) than the corresponding calculated log P (cf., 
ubiquinone and amikacin log P values). The traditional shake-flask method for direct-measure log P is 
thought to be limited to the range (-2 to +5), so methods for prediction of log P would be hard pressed to 






Figure 3. Plot of log S0 (largely SSF type) versus octanol-
water partition coefficient, log P, calculated using the 
RDKit software [15]. 
 
 
Figure 4 shows the distribution of errors determined by averaging the log S0 of those replicate molecules 
measured in different laboratories. The average value of interlaboratory standard deviation is SDavg = 0.17 
log unit. The individual SD values trend to higher values as solubility decreases (Fig. 4b).  
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Figure 4. Interlaboratory reproducibility, as indicated by SD, was determined from averaging log S0 derived 
from different sources. (a) Error distribution for the 870 replicates. (b) Interlaboratory average log S0 plotted 
against the corresponding SD values. The trend suggests that the lowest solubility values have the highest 
errors, but the data scatter is high. 
The molecule showing the poorest reproducibility, with SD = 0.93 log unit (avg. from five sources), is 
clofazimine. It is also among the least soluble molecules in the database, with average log S0 = -9.05. The 
weakly dibasic (pKa 3.83, 7.54 at 37 °C, I = 0.15 M [105]) phenazine antibiotic (MW 473.4 g/mol) is used to 
treat leprosy. The orally-bioavailable molecule has the very unusual characteristic of precipitating and 
accumulating as easily-visible red microcrystals in macrophages [119]. 
Rule of 5 characteristics 
Figure 5 shows the distribution of properties used by Lipinski et al. [120] to define the Rule of 5 as an 
indicator of “drug-likeness.” Frame (a) shows the log P distribution, with the average value of 1.89. About 
80 % of the 6355 entries fall within the range of 0 to 5 (expected range for druglike molecules). Frame (b) 
shows the distribution of molecular weights, with the mean value 280 g/mol. About 95 % of the molecules 
have MW < 500 g/mol (‘good’ range). Frame (c) considers H-bonding characteristics. The red bars (tallest) 
refer to H-bond donor counts (NHD), where 98 % NHD ≤ 5 (‘good’). The black bars (extending to higher 
counts) refer to H-bond acceptors (NHA), where 97 % NHA ≤ 10 (‘good’). For the most part, the database 
molecules are in the expected boundaries of drug-likeness, with log P showing some violations at the high 
end, and more so at the low end for about 20 % of the entries. 
Results and discussion 
Table 1 summarizes the results of the weighted multiple linear regression (MLR) analysis of the Abraham 
solvation equation (ABSOLV), and the ‘trained’ version of Yalkowsky’s general solubility equation (GSE). 
Also listed are the Random Forest regression (RFR) metrics. The 22 quaternary ammonium compounds 
were treated as a separate subset, using just some of the Abraham descriptors. The remaining 6333 
solubility values were subjected to the full MLR analyses. Furthermore, the molecules were considered 
separately in each of four acid-base classes – with reference to predominant charge state at pH 7.4: acids(-
), bases(+), neutrals(0), and zwitterions(±), as well as in combined classes. 
Yalkowsky’s general solubility equation (GSE) 
It was of interest to see how well the GSE (untrained) predicted solubility values in the database. Figure 
6 shows the results of applying Eq. 1 to the acid-base subset data. The first three classes (Figs. 6a-c) have 
similar statistical metrics: r2 = 0.54 to 0.61, RMSE = 1.15 to 1.24, bias = -0.14 to -0.30, and MPP = 37-40 % 
(measure of prediction performance: percentage of the absolute residuals ≤ ±0.5 log unit). The GSE did not 
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perform as well for the zwitterions (Fig. 6d): r2 = 0.07, RMSE = 1.54, bias = +0.34, and MPP =25 %. The 
average calculated log P [15] for the zwitterion set is 0.07 (Table 1), suggesting that the GSE prediction of 
zwitterions is based largely on Tm contributions. When all the classes were combined (n = 6333, excluding 




Figure 5. Rule of 5 property distributions: (a) log P, (b) molecular weight (MW), and (c) number of H-bond 
donors (NHD) and acceptors (NHA). Most of the molecules have ‘druglike’ properties. 
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When the fixed coefficients in Eq. 1 (0.5, -1.0, -0.01) were subjected to regression using weighted MLR, 
the fit improved only slightly for the combined acid-base classes: r2 = 0.60, RMSE = 1.17, n = 6333, but the 
refined coefficients (-0.33, -0.83, - 0.006) were quite different from the traditional values, especially for the 
intercept coefficient (Table 1). This may be due to the negative correlation between the intercept and the 
Tm terms (-82 to -97%). When the molecules were examined by the acid-base classes, the acids most 
resembled the results of the untrained GSE, with coefficients (0.62, -0.94, -0.0115) and metrics: r2 = 0.70, 
RMSE = 1.02, n = 1424. The bases and neutrals indicated a negative intercept, -0.28, with only slightly 
improved metrics (Table 1). The zwitterion class had reversal of signs for both the intercept and the 
temperature dependence coefficients, with the slightly improved metrics: r2 = 0.22, RMSE = 1.28, n = 600. 
Weighted multiple linear regression using Abraham descriptors (ABSOLV) 
Figure 7 displays, by acid-base classes, the results of the weighted MLR analysis using the five Abraham 
ABSOLV descriptors plus the A∙B cross-product term. The statistical metrics were similar for the four 
classes: r2 = 0.61 to 0.73, RMSE = 0.77 (zwitterions) to 1.01 (neutrals), and 40-43 % ‘correct’ values (MPP). 
The performance was slightly better than that of the GSE (trained or untrained), and a lot better in the case 
of zwitterions. The refined ABSOLV coefficients (Table 1) indicate acid-base class differences. These 
coefficients are not similar to the ones reported by Abraham and Le [13]. In MLR, such differences in 
coefficients can arise when different training sets are used, as a result of correlations between descriptors. 
It was found that const:A correlations ranged -50 to -83 % and const:AB correlations ranged +57 to +79 %. 
Table 1. Results of log S0 prediction using three computational models
a 
 
Random Forest regression using RDKit combined with Abraham descriptors and melting points 
Descriptors 
 For the RFR model building, the 193 RDKit (2014 version) descriptors calculated were pooled with 
the Tm (81 % values measured, the rest calculated) and the calculated ABSOLV descriptors. The 
Table 1. Results of log S 0  prediction using three computation models
 a
General Solubility Equation r
2
RMSE n const (mp -25)/100 MolLogP avg MolLogP range sd avg mp range sd
all classes - trained 0.60 1.17 6333 -0.33 -0.60 -0.83 1.89 -8.4 to 17.9 1.9 169 14-375 67
all classes - untrained 0.57 1.23 6333 0.50 -1.00 -1.00
acids 0.70 1.02 1424 0.62 -1.15 -0.94 1.97 -2.5 to 12.8 1.8 178 30-375 59
bases 0.68 0.91 761 -0.27 -0.74 -0.82 3.29 -8.4 to 8.6 1.8 143 25-360 59
neutrals 0.60 1.02 3548 -0.28 -0.90 -0.72 1.86 -7.6 to 17.8 1.8 161 14-372 67
zwitterions 0.22 1.28 600 -1.03 0.11 -0.57 0.07 -5.4 to 7.1 1.4 230 77-343 55
Abraham Solvation Equation r
2
RMSE n const A B S π E V A · B B - A
all classes 0.71 1.00 6333 -0.11 0.07 1.76 -0.104 -1.212 -1.479 0.105
acids 0.72 0.98 1424 -0.21 0.59 1.75 0.02 -1.06 -1.99 0.09
bases 0.71 0.87 761 -0.32 -0.14 1.97 0.08 -1.41 -1.42 0.09
neutrals 0.61 1.01 3548 -0.29 0.11 1.57 0.13 -1.16 -1.57 0.16
zwitterions 0.73 0.77 600 1.50 -1.09 0.76 -0.44 -1.18 -0.63 0.32
quaternaries 0.97 0.27 22 1.86 0.95 -2.19
Random Forest Regression r
2
RMSE n n(tr) n(val) 10-Most Important Descriptors
all classes 0.89 0.60 6355 4449 1906
acids 0.92 0.59 1424 996 428
bases 0.82 0.73 761 532 229
neutrals 0.88 0.68 3548 2483 1065
zwitterions 0.91 0.45 600 420 180
a Descriptors defined in Abbreviations and definitions  section.  n(tr) = training set count; n(val) = count for internal test set validation.
  The calculations with n=6333 count did not include the 22 quaternary ammonium drugs.
MolLogP, MolMR, LabuteASA, Ipc, BertzCT, MW, Chi1, SMR_VSA7, 
HeavyAtomCount, Chi0
MolLogP, MolMR, V, LabuteASA, BertzCT, Chi1n, Chi0n, E, SMR_VSA7, 
mp
MolLogP, NumAromaticCarbocycles , fr_benzene, 
NumAromaticRings , BertzCT, SMR_VSA7, MolMR, SlogP_VSA6, E, 
RingCount
MolLogP, MolMR, LabuteASA, Ipc, MW, Chi1, SMR_VSA10, 
BertzCT, Chi0v, SlogP_VSA2
Chi4v, Chi0, E, MolMR, LabuteASA, BertzCT, MW, Chi4n, Ipc, Chi1
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Abbreviations and definitions section below identifies and defines the most important descriptors used in 
the RFR algorithm. 
Training set and internal validation 
Figure 8a shows the entire training set RFR analysis, with the metrics: r2 = 0.95, RMSE = 0.40,  
bias = -0.007. This is not a good measure of the predictive power of the method. Rather, it indicates how 
well the model can incorporate the information represented by the descriptors and relate it to solubility in 
the training set [66]. The randomly selected internal test set of 1906 solubility values (30 %) are better 
indicators of the ability of the model to predict external tests compounds which are unknown to the 
training process. Figure 8b shows the internal test set prediction results: r2 = 0.89, RMSE = 0.60,  
bias = 0.0002. This performance is to be expected for external test molecules which are well-represented by 
the chemical space of the database, as illustrated below.  
Figure 6. Prediction of the Wiki-pS0 database log S0 values using Yalkowsky’s General Solubility Equation 
(GSE), Eq. 1. The molecules are divided into four acid-base classes with reference to predominant charge 
state at pH 7.4: acids(-), bases(+), neutrals(0), and zwitterions(±). The solid diagonal is the identity line. The 
dashed lines are displaced from the identity line by ±0.5 log. The pie chart refers to the percentage of 
‘correct’ predictions, MPP (measure of prediction performance).  
The bottom section of Table 1 summarizes the analysis metrics, both for the entire data set and for the 
acid-base subsets. The best internal test set performance was found for the zwitterions: r2 = 0.91, RMSE = 
0.45. The right-most column identifies the ten most-important descriptors in the analysis. For the overall 
data, and for the acid, base, and neutral subsets, the most important descriptor is log P. It’s particularly 
noteworthy that log P is not in the top-10 list for the zwitterions. In several of the cases, the second-most 
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important descriptor is molecular refractivity (cf., Abbreviations and definitions for the RDKit terminology). 
Topological indices play particularly important roles in the zwitterion subset. 
 
Figure 7. MLR prediction of log S0 in the Wiki-pS0 database using Abraham Solvation Equation (ABOLV), Eq. 2. 
The molecules are divided into four acid-base classes with reference to predominant charge state at pH 7.4: 
acids(-), bases(+), neutrals(0), and zwitterions(±). The solid diagonal is the identity line. The dashed lines are 
displaced from the identity line by ±0.5 log. The pie chart refers to the percentage of ‘correct’ predictions, 
MPP (measure of prediction performance). 
 
Principal component analysis of thirty of the most important RDKit descriptors 
The principal component analysis (PCA) function, prcomp(), in the factoextra R library was used to 
process the 30-most important descriptors identified in RFR. Figure 9 shows the loading plot based on the 
first two principal components, which account for 63 % of the total variance in the descriptors. Only the 
HallKierAlpha descriptor has a negative PC1 value, with all of the rest of the descriptors being in the 
positive PC1 domain. The close proximity of many of the descriptors to each other suggests high correlation 
between them. Such correlations would be problematic in MLR analysis, but not in RFR. 
Figure 10 shows the scores plots for the solubility data. Frame (a), which considers only the molecules 
with MW < 500 g/mol, shows a very dense but apparently symmetrical distribution about the origin. As MWs 
increase, the points shift in the direction of increasing PC1. Frame (b) shows the molecules with MW > 500 
g/mol. The distribution is sparse and further shifted to increasing PC1 values, as MW values increase. Frame 
(c) shows all the data with the acid-base subset notation. Very large molecules are thinly represented in the 
bottom-right quadrant. Zwitterions tent to be in the negative PC2 half, evenly distributed in PC1. 
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Figure 8. Random Forest regression analysis. The solid diagonals are the identity lines, and the dashed lines 
refer to ±0.5 log deviations. The MPP pie charts refer to percentage of ‘correct’ prediction, with absolute 
residuals ≤0.5 log. (a) Training set using the entire database. (b) Internal test sets, based on 30% of the 
database. The unfilled-circle symbols correspond to the zwitterion internal test set (30% of 600).  
 
  
Figure 9. Principal components analysis loading plot for the 30-most important RFR descriptors. The zoom 
view identifies highly-correlated size-related descriptors. Circles represent the 10-most important descriptors; 
squares represent the second 10-most important descriptors; diamonds represent the remaining ranking.  
 
Validation against four external test sets 
 Four external test sets were selected to explore how well the GSE, ABSOLV, and RFR models 
perform. For each of the test sets, all the test molecules found in the training set were removed, so that the 
prediction was of truly “unknown” molecules. This was not necessary for the traditional GSE model, since it 
requires no training. The observed and calculated values are listed in Appendix Tables A1-A4. 
Figure 11 displays the correlation plots of the GSE calculation for each of the four test sets, using RDKit-
calculated log P. RMSE range from 0.97 to 1.24, as 22 – 42 % of the data are ‘correctly’ predicted (MPP). 
 
ADMET & DMPK 8(1) (2020) 29-77 Aqueous intrinsic solubility of drug molecules using Random Forest regression 




Figure 10. Principal components scores plot for the RFR training set. (a) Molecular weights < 500 g/mol; (b) 
MW > 500 g/mol; (c) “Comet-shaped” distribution for the entire database by acid-base classes. Symbols have 
the same meaning as in Figures 6 and 7. The green diamonds refer to quaternary ammonium drugs. 
 
Figure 12 displays the correlation plots of the ABSOLV weighted MLR analysis for each of the four test 
sets. The ABSOLV model predicted the Hopfinger et al. Test Set 2 better than did the SGE model (RMSE 0.98 
vs. 1.23), but did not do as well with Test Set 1 (RMSE 1.15 vs 0.97). The performances with Test Sets 3 and 
4 were comparable between GSE and ABSOLV models, with RMSE values ranging from 1.02 to 1.24. 
Figure 13 displays the correlation plots of the RFR model for each of the four test sets. The overall 
statistics (r2 = 0.66-0.83, RMSE = 0.75-1.05) indicate that the predictions are better than those in the other 
two models.  
However, there were two main problem areas in the RFR modeling, as indicated by poor fit: (i) Fig. 13a 
shows the outlier pesticides 4,4’-DDT, 2,2’,4,5,5’-PCB and chlordane; (ii) Fig. 13d shows the outlier drugs 
amiodarone, clofazimine, and itraconazole. 
Case (i) can be remedied. The Wiki-pS0 database has very few agrochemicals and no DDT or PCB 
derivatives. We decided to temporarily augment our database with agrochemicals, to see if RFR prediction 
could be improved for Test Set 1 (Fig. 13a). The Huuskonen [35] database of 1297 organic molecules was 
screened with three filters: (a) only compounds with log Sw < -5 would be used; (b) only solids would be 
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considered; and (c) Test Set 1 compounds would be excluded. This process resulted in 115 new entries to 
the augmented database. Figure 14 shows the improved results. By adding a few agrochemicals to the RFR 
training set, r2 increased from 0.83 to 0.90, RMSE decreased from 0.83 to 0.66, bias lowered from -0.23 to 
+0.02, and ‘correct’ predictions increased from 57 to 71 %. The well-known adage that “like predicts like” is 




Figure 11. GSE (“untrained”) prediction (Eq. 1) of the four external test sets. RDKit log P was used. 
 
Antipyrine appears to be poorly fit for reasons related to uncertainty in calculated log P (calc: 1.48, obs: 
0.38). Replacement of the calculated with the observed value improved the antipyrine fit by 0.2 log units, 
suggesting that other descriptors may be problematic. (The improvement in the GSE calculation was 1.2 log 
units for antipyrine.) 
Case (ii) remains problematic - a case of training-set “missing neighbors” problem. As is evident in 
Fig. 13d, amiodarone, clofazimine, and itraconazole are poorly predicted, in part because there are few 
other molecules possessing the properties of these three compounds (cf., upper right edge in scores plot 
Fig.10c) in the database, and also, because RFR cannot extrapolate solubility beyond the range of its 
training data. From the PCA analysis, the five nearest neighbors to amiodarone (log S0 = -10.4), based on 
three principal components, are halofantrine, irbesartan, butaperazine, mifepristone, and probucol. The log 
S0 values for these neighbors show high variance: -8.0, -3.7, -4.3, -5.2, and -8.4, respectively. The RFR-
predicted value for amiodarone is log S0 = -6.8, barely greater than the average value of the five nearest 
neighbors. To do better, the database needs new neighbors in the chemical space close to amiodarone, 
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clofazimine, and itraconazole. Or, better descriptors are needed to define the chemical space, so that truly 
‘similar’ molecules will have nearly the same solubility values. With the three outliers removed, the metric 




Figure 12. ABSOLV weighted MLR prediction (Eq. 2) of the four external test sets. The Abraham Solvation 
Equation was trained with the druglike Wiki-pS0 database. 
 
Prediction of solubility of quaternary ammonium drugs 
Quaternary ammonium compounds are salts, and so do not fall into the category of neutral species 
associated with the log S0 constants studied here. GSE and RFR methods did not produce satisfactory results 
(r2 ~ 0 in both cases) for this subclass of compounds. However, it was possible to come up with a modified 
ABSOLV model for this small group of molecules (n=22), based on the equation: 
log SQA = 1.86 + 0.90 (B-A) - 2.19 Sπ     (4) 
with r2 = 0.97 and RMSE = 0.27, where Sπ in Eq. (4) is the dipolarity/polarizability Abraham descriptor. 
Figure 15 compares the tested calculations. Strong H-bond donors (acids) decrease solubility, whereas 
strong H-bond acceptors (bases) have the opposite effect. High dipolarity/polarizability compounds are 
associate with low solubility. 
  




 Figure 13. RFR prediction of the four external test sets. With 3 outliers removed (n=29) in (d), r2 = 0.82, 










Figure 14. Prediction of Test Set 1 molecules with 
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Figure 15. Prediction models for quaternary ammonium compounds. Here, S0 represents the quaternary 
ammonium salt solubility, SQA. 
Summary 
The properties of the chemical space of druglike molecules in the Wiki-pS0 database of intrinsic aqueous 
solubility were described in considerable detail. The database was used to train two solubility prediction 
models: multiple linear regression (MLR) and Random Forest regression (RFR). The predictivity of the 
models was tested with four external sets of compounds. The MLR model incorporated calculated Abraham 
solvation descriptors (ABSOLV). The RFR model used the aggregate set of Tm (mostly measured values), 
ABSOLV, and RDKit 2D (204 descriptors in all). As a comparative benchmark, the General Solubility Equation 
(GSE), which requires no training, was used to predict the intrinsic solubility of the Wiki-pS0 druglike 
molecules. 
For the intrinsic solubility set, excluding the permanently-charged quaternary amines, RMSE calculated 
as 1.23 (GSE), 1.00 (ABSOLV), and 0.28 (RFR) for the training sets. The intrinsic set was further divided into 
four subsets, based on dominant charge at pH 7.4: acids(-), bases(+), neutrals(0), and zwitterions(±). The 
performances of GSE and ABSOLV were comparable for acids, bases, and neutrals, but for the zwitterionic 
subset, ABSOLV was better. 
For the permanently-charged quaternary amines (n=22), both GSE and RFR did not do well (r2 = 0). It 
was possible to develop a simplified ABSOLV training-set model using just three of the solvation 
descriptors.  
The above comparisons are not entirely satisfactory tests of the predictivity of the three methods. For 
the RFR method, the data are randomly separated into a training set (70%) and an internal test set (30%). 
RMSE = 0.60 and MPP = 76 % ‘correct’ predictions for the internal test set calculation. For the zwitterionic 
subset, RMSE = 0.45 and MPP = 91 %. 
The four external test sets allowed the comparisons of the three models in a uniform way. Test Set 1 
(te1) was compiled by Yalkowsky and Banerjee [18] for testing the GSE. The other three test sets consisted 
of druglike molecules, all solids at room temperature, containing no agrochemicals. Test Set 2 (te2) 
molecules were originally used in the first Solubility Challenge [19,103], and Test Sets 3 (te3) and 4 (te4) 
molecules were used in the second Solubility Challenge [20]. 
The GSE applied to simple organic compounds (te1) indicated RMSE = 0.97 and MPP = 29 % ‘correct’ 
predictions. When experimental log P values are used in Eq. (1) [18], the te1 performance improves: RMSE 
= 0.72 and MPP = 52 %.  
RFR outperformed the other two methods on the whole. When Wiki-pS0 was augmented with 115 
agrochemicals, te1 prediction improved (RMSE = 0.66, MPP = 71 %), and was better than that of GSE. For 
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te2 and te3 drug solubility RFR predictions, RMSE = 0.85 and 0.75, resp., whereas MPP = 50 and 57 %, resp. 
There were three molecules in te4 that RFR did not predict well: amiodarone, clofazimine, and itraconazole. 
Apparently, the current database has limited chemical space coverage in the vicinity of these outliers. With 
the three outliers removed, RMSE = 0.76 and MPP = 41 % for te4. 
Conclusion 
The GSE is popular for its simplicity and easy of calculation. It is a convenient benchmark against which 
to assess new prediction methods. Druglike molecules are expected to be predicted by GSE to within 1.1-
1.2 log unit, or to within 0.5 log unit 22-42 % of the time. However, its performance with zwitterionic 
molecules is limited. The ABSOLV method holds the middle position in the comparisons. The RFR method in 
this study is attractive, both for its predictive performance and ease of use. It is expected to predict druglike 
molecules similar to those in Wiki-pS0 to within 0.6 log unit of the measured values, or within 0.5 log unit 
76% of the time. The RFR software is freely downloadable from open sources.  
Evidently, the evaluated prediction methods cannot match the precision of measured equilibrium 
solubility data. The methods need to be further enhanced. More discriminating descriptors would be 
welcome additions to the openly-available collections. As the amiodarone, clofazimine, and itraconazole 
examples illustrate, there are still under-populated neighborhoods in the chemical space of the currently 
tested database. How effective Wiki-pS0 will be in predicting the solubility of newly-synthesized molecules 
in pharmaceutical research remains to be explored. 
Abbreviations and definitions 
DOA domain of applicability associated with druglike substances, determined by descriptor or 
structural (e.g., Tanimoto indices) similarity. 
DTT Dissolution Titration Template potentiometric method used to determine intrinsic solubility, 
S0 
HH Henderson-Hasselbalch equation [80]; e.g., for monoprotic base, log S = log S0 + log ( 10 
+pKa – 
pH + 1 )  
OOB “Out-of-Bag” built-in validation set of compounds randomly selected by the RFR method, 
which have not been used to train the model. 
pHsat the equilibrium pH of a saturated water solution of compound whose solubility is Sw 
S solubility, ideally expressed in units of mol/L (M), μg/mL, or mg/mL  
S0 “intrinsic” solubility (i.e., the solubility of the uncharged form of the compound) 
Sw “water” solubility, defined by dissolving enough pure free acid/base in distilled water (or 
water containing an inert salt - as ionic strength adjustor) to form a saturated solution. The 
final pH of the suspension, pHsat, and S0 can be calculated by the HH equation (when valid), 
provided the true pKa is known. Compound added in salt form may disproportionate into 
free acid/base, depending on how much solid had been added. Calculation of the pH and S0 
of such salt suspensions can be uncertain.  
SpH  “pH buffer” solubility (i.e., the total solubility of the compound at a measured equilibrated 
pH) 
SSF saturation shake-flask method, the “gold standard” solubility measurement method 
RMSE root-mean-square error: RMSE = [ 1/n Σi (yi
obs - yi
calc)2 ]1/2, where yobs/ ycalc = 
observed/calculated value of log S0 according to model, n = number of measurements of log 
S0 
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r2 squared linear correlation coefficient, r2 = 1 - Σi (yi
obs - yi
calc)2 / Σi (yi
obs - <y>)2 , where y = log 
S0, and <y> is the mean value of log S0  
SD standard deviation: SD = [ 1/n Σi (yi
obs - <y>)2 ]1/2, where n = number of measurements, <y> = 
mean value of log S0  
F F-statistic: F = (n-p-1)/p ∙ Σi (yi
obs - <y>)2 / Σi (yi
obs - yi
calc)2, where p = number of regression 
parameters 
MPP Measure of prediction performance [103]. It refers to the percent of ‘correct’ predictions, as 
defined by the count of absolute residuals |log S0
obs – log S0
calc| ≤ 0.5 divided by the number 
of measurements. MPP is represented as a pie chart in the correlation plots. 
 ntree number of trees specified in the Random Forest regression (RFR) – typically 500 
mtry number of descriptors to use in the node splitting process in RFR – typically a third of the 
descriptors 
nodesize minimum number of data points in the terminal node, beyond which no splitting takes place 
– typically 5 measurements 
Abraham solvation descriptors 
A H-bond total acidity 
B H-bond total basicity 
Sπ dipolarity/polarizability due to solute-solvent interactions between bond dipoles and 
induced dipoles 
E excess molar refraction (dm3 mol-1 / 10); which models dispersion force interaction arising 
from π- and n-electrons of the solute 
V McGowan molar volume (dm3 mol-1 / 100) 
A∙B  acid-base H-bonding product descriptor used in ABSOLV solubility prediction 
 
Most important RDKit descriptors in RFR analysis  
Subdivided Surface Area Molecular Descriptors [121] 
LabuteVSA sum of atomic contributions [51] to the accessible van der Waals surface area  
MolLogP sum of atomic contributions to octanol/water partition coefficient, log P 
MolMR sum of atomic contributions to molar refractivity, MR 
SlogP_VSAk sum of accessible van der Waals surface area for those atoms with atomic contribution 
to log P; k refers to a small domain of atomic-contribution to log P; intended to capture 
hydrophobic/lipophilic effects 
SMR_VSAk sum of accessible van der Waals surface area for those atoms with atomic contribution 
to molar refractivity; k refers to a small domain of atomic-contribution to MR; intended 
to capture molecular size & polarizability 
PEOE_VSAk intended to capture direct electrostatic interactions in a particular range; based on 
iterative equalization of atomic orbital electronegativities [49]. 
 
Complexity descriptors 
BertzCT complexity index, based on size, symmetry, branching, rings, multiple bonds, and heteroatoms 
characteristic of solute [50]. 
Ipc          content information of topological graph [48] - entropy of atomic distribution in solute 
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Topological and electrotopological connectivity indices 
Chi0, Chi0n, Chi0v, Chi1, Chi1n, Chi4n, Chi4v, α – Kier-Hall topological connectivity and shape indices 
[52,53,55] – numerical representations of topology of solute calculated from graphical depiction of the 
molecule 
Atomic and subroup counts, HeavyAtomCount, NumberAromaticCarbocycles, NumberAromaticRings, 
RingCount, fr_benzene 
Availability of the Wiki-pS0 Database 
The entire Wiki-pS0 database is planned to be released in book form: A. Avdeef. Intrinsic Aqueous 
Solubility Data for Pharmaceutical Research. Wiley-Interscience, Hoboken, NJ (under discussion with 
publisher). A sampling is presented in Table A5, with citations to the original literature [122-196]. 
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Table A1. External Test Set 1 (Yalkowsky & Banerjee,1992) 
a
     
 
log S0 (avg., 25 °C) 
  
Tm log P Calculated log S0  
NAME (Wiki-pS0) SD n (°C) (RDKit) GSE ABSOLV RFR 
Acetylsalicylic_Acid -1.64 0.03 28 135 1.31 -1.91 -1.74 -1.92 
Antipyrine 0.45 0.08 9 114 1.48 -1.87 -1.96 -1.18 
Atrazine -3.69 0.15 6 173 1.78 -2.76 -2.54 -3.72 
Benzocaine -2.19 0.12 14 89 1.45 -1.59 -1.97 -1.36 
Chlordane -6.59 0.61 6 25 5.68 -5.18 -5.04 -5.08 
Chlorpyrifos -5.70 0.24 5 43 4.72 -4.40 -3.51 -5.61 
DDT,4,4'- -7.90 0.69 15 109 6.5 -6.84 -5.29 -6.06 
Diazepam -3.81 0.11 10 132 3.15 -3.72 -4.08 -3.68 
Diazinon -3.75 0.10 3 25 3.58 -3.08 -2.81 -4.06 
Diuron -3.84 0.09 3 159 3.09 -3.93 -2.76 -3.55 
Lindane -4.54 0.13 10 113 3.64 -4.02 -3.53 -4.32 
Malathion -3.35 0.02 9 25 2.12 -1.62 -2.39 -3.40 
Nitrofurantoin -3.33 0.11 13 264 0.07 -1.96 -2.06 -2.77 
Parathion -4.27 0.17 12 25 3.27 -2.77 -3.21 -4.08 
PCB,2,2',4,5,5'- -7.40 0.20 19 77 6.62 -6.64 -5.47 -5.84 
Phenobarbital -2.30 0.08 26 175 0.7 -1.70 -2.32 -2.51 
Phenolphthalein -5.08 0.17 2 263 3.56 -5.44 -4.46 -4.15 
Phenytoin -4.07 0.13 30 297 1.77 -3.99 -3.34 -3.45 
Prostaglandin_E2 -2.40 0.09 5 67 3.25 -3.17 -3.38 -3.35 
Testosterone -4.10 0.09 16 155 3.88 -4.68 -3.91 -4.22 
Theophylline -1.38 0.09 15 273 -1.04 -0.94 -1.55 -1.79 
Min. -7.90 0.02 
      Max. 0.45 0.69 
      Mean -3.85 0.17 
      a Melting point of liquids are set to 25 °C (chlordane, diazinon, malathion, and parathion).  The measured log P of antipyrine is 0.38. 
  SD refers to standard deviation from averaging n interlaboratory reported values.  
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Table A2. External Test Set 2 (Hopfinger et al. 2009)       
 




Tm log P Calculated log S0  
NAME (Wiki-pS0) SD n (°C) (RDKit) GSE ABSOLV RFR 
Acebutolol -2.56 0.31 3 119 2.37 -2.81 -2.37 -3.14 
Amoxicillin -2.12 0.07 11 194 0.02 -1.21 -1.71 -1.80 
Bendroflumethiazide -4.30 0.28 6 222 1.63 -3.10 -3.39 -4.31 
Benzocaine -2.19 0.12 14 89 1.45 -1.59 -1.99 -1.19 
Benzthiazide -4.84 0.22 6 232 2.43 -4.00 -4.42 -4.89 
Clozapine -4.60 0.12 4 184 2.03 -3.12 -3.90 -3.57 
Dibucaine -4.04 0.35 3 65 3.49 -3.39 -3.71 -4.06 
Diethylstilbestrol -4.39 0.35 7 171 4.83 -5.79 -3.92 -4.57 
Diflunisal -4.99 0.56 11 214 3.04 -4.43 -3.66 -4.21 
Dipyridamole -5.14 0.12 11 163 -0.02 -0.86 -4.91 -2.84 
Folic Acid -5.96 0.16 6 250 -0.04 -1.71 -2.50 -3.58 
Furosemide -4.47 0.22 22 206 1.89 -3.20 -2.97 -3.58 
Hydrochlorothiazide -2.72 0.10 18 274 -0.35 -1.64 -2.15 -2.91 
Imipramine -4.30 0.26 11 146 3.88 -4.59 -4.36 -4.47 
Indomethacin -5.48 0.22 21 159 3.93 -4.77 -4.72 -5.15 
Ketoprofen -3.41 0.23 24 94 3.11 -3.30 -3.48 -4.19 
Lidocaine -1.82 0.08 20 69 2.58 -2.52 -2.56 -2.62 
Meclofenamic Acid -6.72 0.31 4 257 4.74 -6.56 -4.32 -5.59 
Naphthoic Acid,2- -3.81 0.25 6 185 2.54 -3.64 -2.98 -3.30 
Probenecid -4.83 0.20 4 197 2.20 -3.42 -2.63 -3.33 
Pyrimethamine -4.00 0.47 4 233 2.52 -4.10 -3.93 -3.74 
Salicylic Acid -1.88 0.08 21 158 1.09 -1.92 -1.98 -1.61 
Sulfamerazine -3.11 0.06 7 237 1.17 -2.79 -3.03 -2.83 
Sulfamethizole -2.77 0.12 6 208 1.23 -2.56 -3.29 -2.81 
Terfenadine -7.74 0.71 11 150 6.45 -7.20 -5.98 -6.34 
Thiabendazole -3.97 0.50 4 305 2.69 -4.99 -3.71 -3.56 
Tolbutamide -3.54 0.09 7 129 1.78 -2.32 -2.85 -3.05 
Trazodone -3.27 0.20 6 87 2.36 -2.48 -4.23 -4.22 
Min. -7.74 0.06 
      Max. -1.82 0.71 
      Mean -4.03 0.24 
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Table A3. External Test Set 3 (Avg. Interlab. SD ~0.17)       
 
log S0 (avg., 25 °C) 
  
Tm log P Calculated log S0  
NAME (Wiki-pS0) SD n (°C) (RDKit) GSE ABSOLV RFR 
Acetazolamide -2.38 0.18 11 259 -0.86 -0.98 -1.50 -2.29 
Acetylsalicylic Acid -1.67 0.15 16 142 1.31 -1.98 -1.71 -1.94 
Alclofenac -4.40 0.16 4 92 2.53 -2.70 -2.58 -2.97 
Ambroxol -3.87 0.17 3 234 3.19 -4.78 -3.90 -4.34 
Aripiprazole -6.64 0.21 3 139 4.86 -5.50 -5.18 -5.30 
Atovaquone -6.07 0.18 3 224 5.51 -7.00 -5.13 -6.00 
Atrazine -3.69 0.15 6 173 1.78 -2.76 -2.49 -3.83 
Baclofen -1.78 0.15 4 208 1.86 -3.19 -1.95 -2.51 
Barbital,Buta- -2.22 0.16 10 167 0.79 -1.71 -1.59 -2.30 
Benzthiazide -4.84 0.22 6 232 2.43 -4.00 -4.46 -4.65 
Bromazepam -3.39 0.13 3 193 2.63 -3.81 -3.60 -3.98 
Candesartan cilexetil -6.79 0.15 6 167 6.32 -7.24 -7.78 -6.37 
Carbamazepine -3.22 0.16 15 192 3.39 -4.56 -3.83 -3.96 
Carbazole -5.19 0.19 3 246 3.32 -5.03 -3.74 -4.12 
Carbendazim -4.56 0.19 4 320 1.74 -4.19 -2.39 -3.03 
Cefmenoxime -3.27 0.14 7 187 -0.87 -0.25 -3.66 -2.84 
Cefprozil -1.68 0.20 4 222 0.71 -2.18 -2.35 -2.49 
Celecoxib -5.89 0.18 6 158 3.51 -4.34 -4.77 -4.77 
Cephradine -1.18 0.13 8 140 0.35 -1.00 -2.13 -2.07 
Chlorpropamide -3.17 0.14 7 128 1.74 -2.27 -2.83 -3.11 
Cholic Acid, Deoxy- -4.62 0.15 7 176 4.48 -5.49 -4.44 -4.74 
Cilostazol -4.93 0.13 3 160 3.46 -4.31 -4.35 -4.36 
Cimetidine -1.52 0.22 8 142 0.6 -1.27 -1.71 -2.44 
Ciprofloxacin -3.57 0.18 20 267 1.58 -3.50 -2.97 -3.34 
Cisapride -6.78 0.17 6 110 3.36 -3.71 -4.30 -4.72 
Corticosterone -3.29 0.17 7 182 2.67 -3.74 -3.80 -3.29 
Cortisone Acetate -4.22 0.13 4 222 2.56 -4.03 -3.89 -4.21 
Cyclosporine A -5.03 0.16 6 151 3.27 -4.03 -7.00 -4.45 
Daidzein -5.23 0.13 5 330 2.87 -5.42 -3.11 -4.47 
Desipramine -3.83 0.18 3 100 3.53 -3.78 -4.14 -4.18 
Dexamethasone -3.56 0.18 16 263 1.9 -3.78 -3.55 -3.80 
Diazoxide -3.43 0.22 4 329 1.87 -4.41 -2.34 -3.16 
Diclofenac -5.34 0.18 34 168 4.36 -5.29 -4.15 -5.35 
Diflorasone Diacetate -4.82 0.16 3 223 2.99 -4.47 -4.20 -4.98 
Difloxacin -3.83 0.21 3 211 2.72 -4.08 -4.05 -4.02 
Diltiazem -3.02 0.13 3 210 3.37 -4.72 -4.24 -4.80 
Diphenylamine -3.53 0.14 3 54 3.43 -3.22 -3.22 -3.68 
DOPA,L- -1.76 0.17 6 270 0.05 -2.00 -1.06 -1.79 
Enalapril -1.36 0.21 3 144 1.6 -2.29 -3.01 -2.90 
Estradiol,17α- -5.00 0.18 5 215 3.61 -5.01 -3.98 -4.78 
Estrone -5.38 0.19 8 255 3.82 -5.62 -4.02 -4.79 
Ethoxzolamide -3.76 0.17 3 189 1.34 -2.48 -2.79 -3.00 
Etoposide -3.60 0.20 4 244 1.34 -3.03 -4.51 -3.52 
Eucalyptol -1.66 0.21 3 37 2.74 -2.36 -2.07 -2.22 
Fenbufen -5.18 0.21 10 186 3.4 -4.51 -3.78 -3.72 
Flumequine -3.90 0.19 3 253 2.35 -4.13 -2.83 -3.76 
Flurbiprofen -4.34 0.20 23 111 3.68 -4.04 -3.64 -4.08 
Folic Acid -5.96 0.16 6 250 -0.04 -1.71 -2.53 -3.58 
Ganciclovir -1.78 0.13 3 250 -1.97 0.22 -0.81 -1.88 
Glipizide -5.61 0.21 9 209 2.08 -3.42 -4.33 -4.68 
Griseofulvin -4.52 0.19 15 220 2.69 -4.14 -3.39 -3.56 
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Table A3. Continued…       
 
log S0 (avg., 25 °C) 
  
Tm log P Calculated log S0  
NAME (Wiki-pS0) SD n (°C) (RDKit) GSE ABSOLV RFR 
Haloperidol -5.71 0.17 10 151 4.43 -5.19 -4.24 -4.50 
Ibrutinib -4.85 0.19 7 155 4.22 -5.02 -6.43 -5.08 
Indinavir -4.53 0.16 5 168 2.87 -3.80 -5.45 -4.84 
Indomethacin -5.48 0.22 21 159 3.93 -4.77 -4.72 -5.17 
Indoprofen -4.65 0.21 5 214 3.04 -4.43 -3.65 -4.21 
Ketoconazole -5.47 0.14 11 146 4.21 -4.92 -5.95 -5.38 
Maprotiline -4.62 0.22 5 92 4.21 -4.38 -4.53 -4.95 
Metolazone -3.88 0.21 8 256 2.71 -4.52 -4.12 -4.39 
Nabumetone -4.40 0.21 3 80 3.37 -3.42 -3.66 -4.04 
Naproxen -4.23 0.16 17 153 3.04 -3.82 -3.29 -4.08 
Nelfinavir -6.21 0.20 3 350 4.75 -7.50 -5.62 -5.36 
Nevirapine -3.41 0.14 6 248 2.65 -4.38 -3.54 -3.90 
Nifedipine -4.71 0.15 11 173 2.18 -3.16 -3.22 -4.67 
Nimesulide -4.74 0.14 5 144 2.76 -3.45 -3.92 -4.22 
Norfloxacin -2.88 0.16 19 221 1.27 -2.73 -2.67 -3.13 
Nortriptyline -3.93 0.16 5 214 3.83 -5.22 -4.28 -4.51 
Noscapine -4.48 0.14 3 176 2.88 -3.89 -3.95 -3.84 
Ofloxacin -2.03 0.13 14 254 1.54 -3.33 -3.04 -1.37 
Oxazepam -4.03 0.17 5 206 2.45 -3.76 -3.46 -3.65 
Oxyphenbutazone -3.94 0.19 3 96 3.49 -3.70 -3.49 -4.24 
Papaverine -4.33 0.19 12 147 3.86 -4.58 -4.32 -4.42 
Perphenazine -4.48 0.17 6 97 3.94 -4.16 -4.95 -4.74 
Phenacetin -2.30 0.14 10 135 2.04 -2.64 -1.97 -2.14 
Phenazopyridine -4.02 0.16 7 139 2.66 -3.30 -3.10 -3.36 
Pindolol -3.75 0.15 9 170 1.91 -2.86 -2.45 -2.91 
Pravastatin -4.86 0.15 10 326 2.44 -4.95 -3.45 -3.60 
Prednisolone, Methyl- -3.33 0.18 5 233 1.8 -3.38 -3.65 -3.45 
Primidone -2.53 0.14 4 282 0.54 -2.61 -1.97 -2.31 
Probenecid -4.83 0.20 4 197 2.2 -3.42 -2.62 -3.39 
Promazine -4.45 0.13 4 33 4.24 -3.82 -4.33 -4.74 
Promethazine -4.38 0.19 11 60 4.24 -4.09 -4.29 -4.68 
Repaglinide -4.77 0.17 4 131 5.22 -5.78 -5.22 -6.45 
Resveratrol, trans- -3.75 0.18 7 254 2.97 -4.76 -3.04 -3.60 
Ritonavir -5.17 0.16 5 121 5.91 -6.37 -7.47 -5.80 
Rofecoxib -4.61 0.16 5 207 2.56 -3.88 -3.67 -4.11 
Spironolactone -4.21 0.16 6 135 4.85 -5.45 -5.12 -5.25 
Strychnine -3.38 0.19 6 275 2.09 -4.09 -4.06 -3.30 
Sulfasalazine -6.41 0.14 9 220 1.8 -3.25 -3.85 -4.36 
Sulfathiazole -2.62 0.22 9 202 1.53 -2.80 -3.10 -2.57 
Sulfisomidine -2.16 0.14 3 243 1.48 -3.16 -3.21 -2.84 
Sulfisoxazole -3.13 0.14 3 191 1.67 -2.83 -3.09 -2.81 
Sulindac -4.96 0.21 7 184 4.37 -5.46 -4.34 -5.10 
Tetracaine -3.11 0.11 3 149 2.62 -3.36 -2.61 -2.78 
Tetracycline -3.22 0.15 8 165 -0.37 -0.53 -1.68 -2.72 
Thiacetazone -3.50 0.16 10 225 0.81 -2.31 -2.38 -2.80 
Triamcinolone -3.52 0.21 5 270 0.62 -2.57 -3.10 -3.12 
Triamterene -4.11 0.14 9 313 0.83 -3.21 -4.17 -3.42 
Warfarin -4.78 0.20 11 161 3.61 -4.47 -3.84 -4.29 
Xanthine -3.60 0.21 3 300 -1.06 -1.19 -1.24 -2.69 
Min. -6.79 0.11 
      Max. -1.18 0.22 
      Mean -4.03 0.17 
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Table A4. External Test Set 4 (Avg. Interlab. SD ~0.62)       
 
log S0 (avg., 25 °C) 
  
Tm log P Calculated log S0  
NAME (Wiki-pS0) SD n (°C) (RDKit) GSE ABSOLV RFR 
Amantadine -2.19 0.50 3 180 1.91 -2.96 -1.95 -1.96 
Amiodarone -10.40 0.50 5 156 6.94 -7.75 -7.68 -6.77 
Amodiaquine -5.49 0.65 3 208 5.18 -6.51 -4.86 -5.57 
Bisoprolol -2.09 0.59 3 100 2.37 -2.62 -2.51 -2.50 
Bromocriptine -5.50 0.51 5 217 3.19 -4.61 -5.65 -5.12 
Buprenorphine -6.07 0.83 3 210 4.41 -5.76 -5.54 -5.20 
Chlorprothixene -5.99 0.51 6 98 5.19 -5.42 -4.96 -5.23 
Clofazimine -9.05 0.93 5 211 7.49 -8.85 -7.42 -6.88 
Curcumin -5.36 0.68 3 177 3.37 -4.39 -4.22 -4.67 
Danazol -6.10 0.52 10 229 4.22 -5.76 -5.01 -4.69 
Didanosine -1.24 0.54 3 162 -0.21 -0.66 -1.75 -1.34 
Diflunisal -4.99 0.56 11 214 3.04 -4.43 -3.70 -4.02 
Diphenhydramine -3.21 0.55 4 169 3.35 -4.29 -3.47 -3.41 
Etoxadrol -1.96 0.55 3 124 2.81 -3.30 -2.96 -3.14 
Ezetimibe -4.94 0.51 4 165 4.89 -5.79 -4.62 -5.55 
Fentiazac -5.84 0.65 4 161 4.76 -5.62 -5.40 -4.90 
Iopanoic Acid -5.49 0.66 3 155 3.74 -4.54 -5.94 -4.85 
Itraconazole -8.98 0.61 3 165 5.58 -6.48 -8.45 -6.50 
Miconazole -5.82 0.50 6 161 6.45 -7.31 -5.86 -5.71 
Mifepristone -5.22 0.75 4 194 5.41 -6.60 -5.96 -5.82 
Omeprazole -3.70 0.50 3 156 2.9 -3.71 -3.70 -3.88 
Pioglitazone -6.20 0.66 4 184 3.16 -4.25 -4.15 -4.44 
Procaine -2.30 0.60 3 61 1.77 -1.63 -2.27 -2.55 
Quinine -3.06 0.57 7 177 3.17 -4.19 -3.74 -2.85 
Raloxifene -6.82 0.56 6 145 6.08 -6.78 -6.70 -6.18 
Rifabutin -4.09 0.66 3 176 4.62 -5.63 -6.88 -5.22 
Saquinavir -5.92 0.58 3 350 3.09 -5.84 -5.95 -4.92 
Sulfadimethoxine -3.74 0.70 3 204 0.88 -2.17 -2.89 -3.17 
Tamoxifen -7.52 0.72 7 98 6.00 -6.23 -5.55 -6.09 
Telmisartan -6.73 0.84 5 262 7.26 -9.13 -9.03 -7.15 
Terfenadine -7.74 0.71 11 150 6.45 -7.20 -6.03 -6.61 
Thiabendazole -3.97 0.50 4 305 2.69 -4.99 -3.75 -3.62 
Min. -10.40 0.50 
      Max. -1.24 0.93 
      Mean -5.24 0.62 
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Table A5.   Listing of external test set 4 solubility values  from the Wiki-pS 0  database 
a
184.   Amantadine
SMILES C12(N)CC3CC(C1)CC(C2)C3
RN 768-94-5
MW 151.25 g/mol Calc. Abraham Solvation Descriptors
mp 180 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 14.4 kJ/mol 0.21 0.64 0.68 0.84 1.29
pK a (acid) .... pK a (base) 10.6
log S0 SD t (
oC) S0(mg/mL) Num. pH Ref. Sep.
-2.78 0.50 23 0.25 [154] centrif 24h; pH10 (67mM PBS,I=0.16M); CLND-N2 det
-1.95 0.50 25 1.7 [100] no sep CheqSol
-1.85 0.17 26 2.1 [102] no sep CheqSol: n=3, I=0.27M
203.   Amiodarone
SMILES C1=CC=CC2=C1C(=C(O2)CCCC)C(=O)C3=CC(=C(OCCN(CC)CC)C(=C3)I)I
RN 1951-25-3
MW 645.32 g/mol Calc. Abraham Solvation Descriptors
mp 156 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 22.4 kJ/mol 0.00 1.30 2.49 3.33 3.75
pK a (acid) .... pK a (base) 8.7
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-11.06 0.50 23 0.000006 11 [96] (BH)5; BH.H2PO4(s ); (BH)2HPO4(s ) 24h; 0.15M phosphate, H3PO4 titr
-10.22 0.97 25 0.000039 6 [192] (BH)2 filt µSOL - noisy
-10.66 0.59 25 0.000014 [190] filt or centrif 24h; pH7.4 (0.1M phosphate)
-9.68 0.59 25 0.00013 [102] no sep CheqSol
-10.26 0.59 37 0.000035 [147] filt or centrif 24h; pH7.0
208.   Amodiaquine
SMILES C1=CC(=CC2=NC=CC(=C12)NC3=CC=C(C(=C3)CN(CC)CC)O)Cl
RN 86-42-0
MW 355.87 g/mol Calc. Abraham Solvation Descriptors
mp 208 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 24.3 kJ/mol 0.63 1.52 2.32 2.70 2.74
pK a (acid) 10.4 pK a (base) 9.1
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.94 0.65 25 0.41 [102] no sep CheqSol
-5.79 0.52 26 0.58 [19] no sep CheqSol: n=7, I=0.17M
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660.   Bisoprolol
SMILES CC(C)NCC(COc1ccc(cc1)COCCOC(C)C)O
RN 66722-44-9
MW 325.44 g/mol Calc. Abraham Solvation Descriptors
mp 100 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln -4.7 kJ/mol 0.29 1.77 1.37 1.14 2.74
pK a (acid) .... pK a (base) 9.6
log S0 SD t (
oC) S0(mg/mL) Num. pH Ref. Sep.
-1.46 0.30 25 11 [108] no sep CheqSol/pSOL
-2.16 0.59 25 2.2 [158]
-2.67 0.59 37 0.70 5 [129] filt 24h
678.   Bromocriptine
SMILES [C@@]56(N(C([C@@](NC([C@@H]4C=C3C1=CC=CC2=C1C(=C(Br)[NH]2)C[C@H]3N(C4)C)=O)(C(C)C)O5)=O)[C@H](C(=O)N7[C@H]6CCC7)CC(C)C)O
RN 25614-03-3
MW 654.59 g/mol Calc. Abraham Solvation Descriptors
mp 217 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 13.5 kJ/mol 0.79 3.66 4.28 4.33 4.48
pK a (acid) .... pK a (base) 5.4
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.55 0.18 20 1.9 8 [137]      no detail about buffs or incub time
-5.50 0.59 23 2.1 [29]      
-4.70 0.59 25 13 [114]      no sep pSOL
-5.65 0.37 37 1.5 [194] no sep μDISS: 20h; pH 6.5 (29mM phosphate,106mM NaCl)
-6.00 1.09 37 0.65 [194]      20h; pH6.5 (29mM phosphate,106mM NaCl)
690.   Buprenorphine
SMILES O[C@]([C@@H]1([C@]2([C@H]3([C@]45([C@@]([C@H]([N@@](CC4)(CC4CC4))(Cc4c5c(O3)c(O)cc4))(C1)(CC2))))(OC)))(C(C)(C)C)(C)
RN 52485-79-7
MW 467.65 g/mol Calc. Abraham Solvation Descriptors
mp 210 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 7.7 kJ/mol 0.59 1.66 1.67 2.42 3.64
pK a (acid) 9.6 pK a (base) 8.5
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.94 0.83 23 0.54 [86] no detailed; BHCl salt assumed
-5.33 0.83 23 2.2 12 [145] (XH)2*** 15h; 50mM phosphate
-6.93 0.12 32 0.054 5 [171] (XH2)2; XH2.Cl(s) filt 30h; 50mM phosphate assumed
824.   Chlorprothixene
SMILES C1=C(Cl)C=CC3=C1\C(C2=C(C=CC=C2)S3)=C/CCN(C)C
RN 113-59-7
MW 315.87 g/mol Calc. Abraham Solvation Descriptors
mp 98 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 18.6 kJ/mol 0.00 0.88 1.57 2.21 2.40
pK a (acid) .... pK a (base) 9.1
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.97 0.35 23 0.34 10 [96] BH.H2PO4(s) 24h; 0.15M phosphate; H3PO4 titr; Cl from sample
-5.25 0.03 23 1.8 5 [80] B2* filt µSOL: 24h
-6.30 0.51 25 0.16 [102] no sep CheqSol
-5.82 0.51 25 0.48 [117] no sep pSOL
-6.75 0.09 26 0.056 [19] no sep CheqSol: n=9; Form_I












































ADMET & DMPK 8(1) (2020) 29-77 Aqueous intrinsic solubility of drug molecules using Random Forest regression 
doi: http://dx.doi.org/10.5599/admet.766 71 








883.   Clofazimine
SMILES C1=CC=CC3=C1N(C2=CC(=NC(C)C)C(=CC2=N3)NC4=CC=C(Cl)C=C4)C5=CC=C(Cl)C=C5
RN 2030-63-9
MW 473.41 g/mol Calc. Abraham Solvation Descriptors
mp 211 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 28.2 kJ/mol 0.19 1.28 2.34 3.50 3.45
pK a (acid) .... pK a (base) 8.7
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-8.67 0.93 25 0.0010 [190]      filt or centrif 24h; pH7.4 (0.1M phosphate)
-9.52 0.08 25 0.00014 29 [188] B2 filt 5d; BHCl+NaOH, looks good
-8.76 0.93 37 0.00081 [164] pH7.2 isotonic buff
-10.10 0.19 37 0.000037 93 [124] (BH)3; BH.Cl (s ); BH.H2Cit(s ) filt 24h; buff-free
-7.63 0.08 37 0.011 6 [163] B2 looks good
923.   Curcumin
SMILES Oc1ccc(cc1OC)/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2
RN 458-37-7
MW 368.38 g/mol Calc. Abraham Solvation Descriptors
mp 177 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 16.7 kJ/mol 0.55 1.67 2.85 2.30 2.77
pK a (acid) 7.5 pK a (base) ....
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.69 0.68 23 0.75 [181] filt 48h
-4.58 0.68 25 9.8 [182] 24h
-5.83 0.68 25 0.55 [134] 24h
971.   Danazol
SMILES [C@@H]23[C@H]([C@H]1[C@]([C@@](C#C)(O)CC1)(C)CC2)CCC4=CC5=C(C[C@]34C)C=NO5
RN 17230-88-5
MW 337.46 g/mol Calc. Abraham Solvation Descriptors
mp 229 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 20.9 kJ/mol 0.40 1.03 2.38 2.14 2.67
pK a (acid) .... pK a (base) ....
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-7.44 1.37 21 0.01 [98]      centrif x 3 intrin; 43d, mini-SF
-5.77 0.52 25 0.58 [139]
-5.57 0.19 25 0.90 [86], [149]      centrif 48h; pH6.8 (10mM phosphate)
-5.92 0.52 37 0.40 [166]      filt 17h
-6.21 0.52 37 0.21 [147]
-5.70 0.03 37 0.67 [143] no sep μDISS: 2h; pH6.5 (phosphate)
-6.00 0.52 37 0.34 [146]
-5.81 0.52 37 0.52 [123]
-5.51 0.52 37 1.05 [159] filt 48h; pH5.5 (McIlvaine,I=0.1M NaCl)
-6.14 0.31 37 0.25 2 [132] 24h
983.   DDI<2',3'-Dideoxyinosine><Didanosine>
SMILES O=C1c2c(N=CN1)[n@@](cn2)([C@@H]1(O[C@H](CO)(CC1)))
RN 69655-05-6
MW 236.23 g/mol Calc. Abraham Solvation Descriptors
mp 162 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 16.8 kJ/mol 0.48 1.78 2.17 1.90 1.60
pK a (acid) 9.0 pK a (base) 1.2
log S0 SD t (
oC) S0(mg/mL) Num. pH Ref. Sep.
-0.94 0.01 25 27 [87] APDS 22(185)
-0.93 0.07 25 28 8 [195] A2H* 24h; buff-free; good data
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1042.   Diflunisal
SMILES C2=C(C1=CC=C(C(=C1)C(O)=O)O)C(=CC(=C2)F)F
RN 22494-42-4
MW 250.20 g/mol Calc. Abraham Solvation Descriptors
mp 214 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 32.2 kJ/mol 0.70 0.44 1.50 1.55 1.63
pK a (acid) 2.5 pK a (base) ....
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.39 0.56 23 1.0 [99]      centrif, then filt 48h; no ISA, buff-free
-5.46 0.60 23 0.87 9 [133] noisy data; pH1 used;  buff points complex
-4.61 0.56 25 6.2 [168]      centrif, then filt pH2
-3.98 0.58 25 26 [103]      no sep CheqSol: Form_1
-4.52 0.17 25 7.6 [103]      no sep CheqSol: Form_2
-5.43 0.10 25 0.93 [103]      no sep CheqSol: Form_3
-5.94 0.13 25 0.29 [103]      no sep CheqSol: Form_4
-4.60 0.56 25 6.3 [110]      no sep CheqSol
-4.84 0.56 37 3.6 [110]      no sep CheqSol
-5.13 0.04 37 1.9 4 [162] err in Fig 1 correctd
-4.47 0.56 37 8.5 [168]      centrif, then filt pH2
1065.   Diphenhydramine<Benadryl>
SMILES CN(C)CCOC(c1ccccc1)c2ccccc2
RN 58-73-1
MW 255.36 g/mol Calc. Abraham Solvation Descriptors
mp 169 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 13.1 kJ/mol 0.00 0.95 1.43 1.36 2.19
pK a (acid) .... pK a (base) 8.8
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-2.59 0.55 23 656 [148]
-3.81 0.55 23 40 [154] centrif 24h; pH7.4 (67mM PBS,I=0.16M); CLND-N2 det
-2.95 0.04 26 286 [102] no sep CheqSol: n=2, I=0.16M
-3.42 0.55 38 97 [156] filt 2.5h? pH7.4 (67mM phosphate; I=0.17M)
1191.   Etoxadrol
SMILES C3=C(C2(OC(C1CCCCN1)CO2)CC)C=CC=C3
RN 28189-85-7
MW 261.36 g/mol Calc. Abraham Solvation Descriptors
mp 124 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 8.2 kJ/mol 0.15 1.05 1.24 1.20 2.13
pK a (acid) .... pK a (base) 8.2
log S0 SD t (
oC) S0(mg/mL) Num. pH Ref. Sep.
-2.52 0.04 20 0.79 14 [152] (BH)5; BH.Cl(s) 48h; buff-free
-1.97 0.55 30 2.8 [152]
-1.34 0.55 40 12 [152]
1198.   Ezetimibe
SMILES O[C@@H](CC[C@@H]1([C@H](N(C1=O)c1ccc(F)cc1)(c1ccc(O)cc1)))(c1ccc(F)cc1)
RN 163222-33-1
MW 409.43 g/mol Calc. Abraham Solvation Descriptors
mp 165 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 15.8 kJ/mol 0.81 1.77 2.61 2.65 2.94
pK a (acid) 10.3 pK a (base) ....
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-4.55 0.05 23 11 2 [153]      anhydrate & HA.H2O in water
-4.49 0.65 23 13 2 [153]      HA & HA.H2O in 0.1 M HCl
-5.39 0.54 23 1.7 [176]      filt 168h; buff-free
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1230.   Fentiazac
SMILES c1ccc(cc1)c2nc(c(s2)CC(=O)O)c3ccc(cc3)Cl
RN 18046-21-4
MW 329.801 g/mol Calc. Abraham Solvation Descriptors
mp 161 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 33.8 kJ/mol 0.57 0.81 2.29 2.62 2.29
pK a (acid) 4.0 pK a (base) 2.4
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-6.31 0.65 5 0.16 [141]
-6.23 0.65 25 0.20 [141]
-4.91 0.33 25 4.0 3 [131] filt 24h
-6.13 0.65 37 0.25 [141]
1536.   Iopanoic_Acid
SMILES C1=C(C(=C(C(=C1I)CC(C(O)=O)CC)I)N)I
RN 96-83-3
MW 570.93 g/mol Calc. Abraham Solvation Descriptors
mp 155 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 35.1 kJ/mol 0.85 0.74 2.16 2.91 2.37
pK a (acid) 4.6 pK a (base) ....
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.89 0.66 23 0.73 [99] centrif, then filt 48h; no ISA, buff-free
-4.77 0.66 23 9.7 [169]
-5.65 0.66 37 1.3 [150] pH7.4
1600.   Itraconazole
SMILES [C@]6(C1=C(C=C(Cl)C=C1)Cl)(O[C@@H](COC2=CC=C(C=C2)N5CCN(C3=CC=C(C=C3)N4C(N(C(CC)C)N=C4)=O)CC5)CO6)C[N]7C=NC=N7
RN 84625-61-6
MW 705.65 g/mol Calc. Abraham Solvation Descriptors
mp 165 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 19.2 kJ/mol 0.00 2.95 4.54 4.65 5.00
pK a (acid) .... pK a (base) 5.4
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-8.48 2.46 21 0.0023 [98] centrif x 3 intrin; pH=pKa+2; 14d, mini. SF
-8.85 0.61 25 0.0010 [167] est. as ~1ng/mL
-9.51 0.61 37 0.0002 [147]
1767.   Miconazole
SMILES C1=C(C=CC(=C1Cl)COC(C[N]2C=NC=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
RN 22916-47-8
MW 416.13 g/mol Calc. Abraham Solvation Descriptors
mp 161 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 21.7 kJ/mol 0.00 0.79 2.33 2.37 2.72
pK a (acid) .... pK a (base) 6.6
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.67 0.33 23 0.89 13 [80] B2*** filt µSOL: 18h; 1%DMSO,multi-set avg data
-5.07 0.09 25 3.5 [19] no sep CheqSol: n=5
-6.01 0.40 25 0.41 [80]      no sep pSOL
-5.70 0.50 25 0.83 [102] no sep CheqSol
-5.88 0.50 25 0.55 [117] no sep pSOL
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1769.   Mifepristone
SMILES [C@H]23C(=C1C(=CC(=O)CC1)CC2)[C@H](C[C@]4([C@H]3CC[C@]4(C#CC)O)C)C5=CC=C(C=C5)N(C)C
RN 84371-65-3
MW 429.60 g/mol Calc. Abraham Solvation Descriptors
mp 194 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 16.1 kJ/mol 0.31 1.58 3.09 2.61 3.52
pK a (acid) .... pK a (base) 5.1
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.75 0.08 21 0.76 [97]      centrif intrin; mini-SF (pH=pKa±2)
-6.04 0.27 23 0.39 9 [96] B2H; B.B2H.H2PO4(s) 24h; 0.15M phosphate, H3PO4 titr, Cl-free
-4.54 0.04 23 13 3 [80]      filt µSOL: 21h; pKa 5.23±0.05 from E. Bosch
-4.53 0.06 37 13 [170]      Uniprep filt 24h; pH4.5 (50mM? OAc)
1957.   Omeprazole
SMILES Cc1cnc(c(c1OC)C)CS(=O)c2[nH]c3ccc(cc3n2)OC
RN 73590-58-6
MW 345.42 g/mol Calc. Abraham Solvation Descriptors
mp 156 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 20.4 kJ/mol 0.35 2.05 3.18 2.67 2.52
pK a (acid) 8.6 pK a (base) 4.4
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-3.42 0.50 23 131 [94] not stable for 24h unless pH>10
-4.30 0.50 23 17 [155]      filt 72-168h; buff-free
-3.29 0.09 37 177 [143] no sep μDISS: 2h; pH6.5 (phosphate)
2166.   Pioglitazone
SMILES CCc1ccc(nc1)CCOc2ccc(cc2)CC3C(=O)NC(=O)S3
RN 111025-46-8
MW 356.44 g/mol Calc. Abraham Solvation Descriptors
mp 184 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 30.3 kJ/mol 0.34 1.64 2.37 2.33 2.66
pK a (acid) 6.5 pK a (base) 5.4
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-6.62 0.19 23 0.085 5 [193]           good data but no details
-6.77 0.19 25 0.060 44 [135]      centrif 24h str+24h sed; MS-MUB buff
-6.16 0.55 25 0.25 [108]      no sep CheqSol/pSOL
-5.29 0.66 25 1.8 [172]           24h;pH7.4(0.1M phosphate)
2220.   Procaine<Novacaine>
SMILES C1=C(C(OCCN(CC)CC)=O)C=CC(=C1)N
RN 59-46-1
MW 236.32 g/mol Calc. Abraham Solvation Descriptors
mp 61 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 6.7 kJ/mol 0.23 1.27 1.62 1.11 1.98
pK a (acid) .... pK a (base) 8.4
log S0 SD t (
oC) S0(mg/mL) Num. pH Ref. Sep.
-2.27 0.60 23 1.3 [138]      
-1.72 0.08 25 4.5 [102] no sep CheqSol: n=3, I=0.19M
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2444.   Quinine
SMILES [C@@H]2(N1C[C@H](C=C)[C@H](CC1)C2)[C@@H](C3=CC=NC4=C3C=C(C=C4)OC)O
RN 1407-83-6
MW 324.42 g/mol Calc. Abraham Solvation Descriptors
mp 177 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 14.6 kJ/mol 0.23 1.81 1.71 2.40 2.55
pK a (acid) .... pK a (base) 8.6
log S0 SD t (
oC) S0(mg/mL) Num. pH Ref. Sep.
-2.44 0.57 23 1.2 [99]      centrif, then filt 48h; no ISA, buff-free
-2.82 0.05 25 0.49 [113]      no sep pSOL
-2.81 0.57 25 0.50 [102] no sep CheqSol
-3.10 0.57 25 0.26 [122]
-3.25 0.12 25 0.18 [126]      centrif, then filt 48+24h; pH11.5
-2.79 0.04 25 0.53 [19] no sep CheqSol: n=2, I=0.16M
-4.11 0.19 37 0.025 5 [177] BH2.SO4(s) 24h
2475.   Raloxifene<Keoxifene>
SMILES C(=O)(c1c(-c2ccc(O)cc2)sc3c1ccc(O)c3)c4ccc(OCCN5CCCCC5)cc4
RN 84449-90-1
MW 473.5828 g/mol Calc. Abraham Solvation Descriptors
mp 145 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 27.6 kJ/mol 1.00 1.85 3.12 3.75 3.54
pK a (acid) 8.3 pK a (base) 8.7
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.94 0.73 25 0.54 6 [151] XH3.Cl(s) filt 24h? OAc, phosphate; NOISY
-7.53 0.56 25 0.014 [196] XH3.Cl(s) filt 24h? OAc, phosphate; salt assumed
-7.18 0.56 30 0.031 [196] XH3.Cl(s) filt 24h? OAc, phosphate; salt assumed
-6.76 0.56 35 0.082 [196] XH3.Cl(s) filt 24h? OAc, phosphate; salt assumed
-6.45 0.56 40 0.17 [196] XH3.Cl(s) filt 24h? OAc, phosphate; salt assumed
-6.21 0.56 50 0.29 [196] XH3.Cl(s) filt 24h? OAc, phosphate; salt assumed
2497.   Rifabutin
SMILES C(=O)(OC1C(C(OC)C=COC2(C(=O)c3c4c(C(=O)C(=C5C4=NC6(N5)CCN(CC(C)C)CC6)NC(=O)C(=CC=CC(C(O)C(C(O)C1C)C)C)C)c(c(c3O2)C)O)C)C)C
RN 72559-06-9
MW 847.03 g/mol Calc. Abraham Solvation Descriptors
mp 176 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln -9.5 kJ/mol 1.31 4.39 4.43 4.24 6.47
pK a (acid) 8.0 pK a (base) 10.0
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-3.65 0.66 23 190 [86] no details
-3.75 0.66 23 150 [175]
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2571.   Saquinavir
SMILES [C@@H]15[C@@H](CN([C@@H](C1)C(=O)NC(C)(C)C)C[C@@H](O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC3=C(C=C2)C=CC=C3)CC(=O)N)CC4=CC=CC=C4)CCCC5
RN 127779-20-8
MW 670.85 g/mol Calc. Abraham Solvation Descriptors
mp 350 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 14.7 kJ/mol 1.46 3.89 5.55 4.09 5.30
pK a (acid) .... pK a (base) 6.8
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-5.29 0.69 23 3.4 3 [186] BH.z(s); B2H no details
-6.11 0.54 25 0.52 10 [130] BH.Cl(s); B2H 24h
-6.28 0.58 37 0.35 [187] pH 5 & 6.5 (28.7mM phosphate, 103mM NaCl)
2642.   Sulfadimethoxine
SMILES C1=C(N=C(N=C1N[S](C2=CC=C(N)C=C2)(=O)=O)OC)OC
RN 122-11-2
MW 310.334 g/mol Calc. Abraham Solvation Descriptors
mp 204 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 30.8 kJ/mol 0.59 1.78 2.77 2.17 2.12
pK a (acid) 6.0 pK a (base) 2.5
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-2.97 0.70 23 331 [127]      pH7.4
-4.22 0.04 25 19 36 [173] (XH2)2* I=0.1M, multiple buffs
-3.87 0.70 37 42 [184]      
2694.   Tamoxifen
SMILES C1=CC(=CC=C1\C(=C(C2=CC=CC=C2)\CC)C3=CC=CC=C3)OCCN(C)C
RN 10540-29-1
MW 371.52 g/mol Calc. Abraham Solvation Descriptors
mp 97.8 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 10.0 kJ/mol 0.00 1.11 1.85 2.06 3.17
pK a (acid) .... pK a (base) 8.7
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-8.49 0.89 21 0.0012 [97]      centrif intrin; mini-SF (pH=pKa±2)
-8.54 0.60 21 0.0011 [98]      centrif x 3 intrin; 37d; pH=pKa+2
-7.13 0.19 23 0.027 6 [140]      filt µSOL: 18h; 0.5%DMSO, noisy
-6.87 0.72 23 0.050 [165] filt 3h str+15h sed; pH6.5 (50mM phosphate)
-7.15 0.72 25 0.026 [190]      filt or centrif 24h; pH7.4 (0.1M phosphate)
-7.72 0.53 25 0.0071 [115]      no sep pSOL-cosolv extrap
-6.76 0.12 37 0.064 [142]      no sep
2706.   Telmisartan
SMILES CCCc1nc2c(cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C)C
RN 144701-48-4
MW 514.62 g/mol Calc. Abraham Solvation Descriptors
mp 262 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 41.4 kJ/mol 0.57 1.59 3.56 4.61 3.98
pK a (acid) 3.6 pK a (base) 6.2
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-6.53 0.12 23 0.15 10 [160] X2H; Na.X2H(s); XH3.XH2.Cl3(s) no details
-5.88 0.31 23 0.68 7 [174] X2H; XH2.Cl(s) 24h; buff, robotics
-6.23 0.22 25 0.30 4 [157] X2H5; XH3.XH2.Cl3(s) centrif, then filt 120h; buff-free
-6.88 0.04 37 0.067 4 [183] XH2.Cl(s) centrif 48h; USP phosphate; 0.1M NaCl assumed
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 RN – Registry number (CAS). ΔHsol – calculated [9] heat of solubility, used to adjust data to a standard temperature (25 °C). pKa – 
calculated for strongest acid and weakest base groups. Num.pH – number of SpH measurements in the log S – pH profile. *,**,*** 
indicate small, moderate, extensive concentration of aggregate/complex.  
 
2718.   Terfenadine
SMILES C1=CC=CC=C1C(C3CCN(CCCC(C2=CC=C(C(C)(C)C)C=C2)O)CC3)(C4=CC=CC=C4)O
RN 50679-08-8
MW 471.69 g/mol Calc. Abraham Solvation Descriptors
mp 149.6 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 4.5 kJ/mol 0.63 1.80 2.04 2.55 4.01
pK a (acid) .... pK a (base) 8.8
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-7.94 1.09 21 0.0054 [98]      centrif x 3 intrin; 36d; pH=pKa+2
-8.86 0.42 22 0.00065 2 [125] 24h; I=20mM buffs
-7.25 0.39 25 0.026 6 [178] BH.H2PO4(s) 96h; 8mg/mL added, H3PO4 titr
-7.06 0.39 25 0.041 5 [178] BH.Cl(s) 96h; 8mg/mL added, buff-free, HCl titr
-7.09 3.13 25 0.038 5 [178] BH.Lac(s) 96h; 8mg/mL added, LacH titr
-7.16 0.46 25 0.033 5 [178] BH.Cl(s) 96h; 8mg/mL added, buff-free, MeSO3H titr
-8.79 0.69 25 0.00076 27 [179] BH.Cl(s); (BH)3 36-96h in LacH;en buffs
-8.03 0.17 25 0.0044 [190] filt or centrif 24h; pH7.4 (0.1M phosphate)
-8.40 0.71 25 0.0019 [100] no sep CheqSol-cosolv extrap
-7.65 0.35 30 0.010 16 [191] (BH)2.HCit(s); BH.H2Cit(s) filt 48h; 50mM Cit
-6.89 0.15 37 0.061 2 [143], [144] BH.Cl(s) no sep μDISS: 2h; pH 2.5, 6.5 (phosphate)
2755.   Thiabendazole
SMILES C3=CC1=C([NH]C(=N1)C2=CSC=N2)C=C3
RN 148-79-8
MW 201.25 g/mol Calc. Abraham Solvation Descriptors
mp 304.5 oC A (Σα2
H ) B (Σβ2
H ) S (π2) E (R2) Vx
Calc. ΔHsoln 36.0 kJ/mol 0.35 0.72 1.94 2.22 1.40
pK a (acid) .... pK a (base) 4.7
log S0 SD t (
oC) S0(μg/mL) Num. pH Ref. Sep.
-4.39 0.08 25 8.2 9 [128] (BH)2**; BH.Cl(s) 24h; buff-free, HCl titr
-4.41 0.19 25 7.8 12 [128] B2***; BH.BH2; BH2.HPO4(s); BH2.(H2PO4)2(s) 24h; H3PO4 titr, buff-free
-3.60 0.50 25 50 [185]
-3.48 0.11 25 66 [103] no sep CheqSol
a RN - Registry Number (CAS). ΔHsoln - calculated [9] heat of solubility, used to adjust data to a standard temperature (25 
oC).  pK a  - calculated for strongest acid and weakest base groups.
   Num. pH - number of SpH measurements in the log S -pH profile.  *,**,*** indicate small, moderate, extensive concentration of aggregate/complex.
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